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Abstract 
 
 
 
MEDICATION-RELATED PROBLEMS IN OLDER ADULTS: A FOCUS ON 
UNDERUSE OF WARFARIN AND WARFARIN-ANTIBIOTIC INTERACTIONS 
 
 
By Parinaz K. Ghaswalla, PhD  
 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy at Virginia Commonwealth University 
 
 
Virginia Commonwealth University, 2011 
 
 
Major Advisor: Dr. Patricia W. Slattum, Pharm.D., Ph.D. 
Director, Geriatric Pharmacotherapy Program 
Associate Professor, Department of Pharmacotherapy and Outcomes Science 
 
 
The work presented in this dissertation focuses on two important medication-
related problems in older adults, that is, untreated indication and drug-drug interactions, 
specifically with respect to a high-risk medication such as warfarin. Warfarin is a 
challenge to use in clinical practice due to its narrow therapeutic index, variability in 
dose-response and its interactions with numerous foods and drugs. This dissertation 
presents the research from two projects. In the first project the prevalence and predictors 
of warfarin use in nursing home (NH) residents with atrial fibrillation (AF), and use of 
secondary stroke prevention strategies was determined, in order to understand the 
patterns of anticoagulant use in frail NH residents and to identify patient characteristics 
associated with warfarin use. In the second project the effect of oral antibiotics on 
anticoagulation outcomes, when prescribed concomitantly with warfarin, was 
	   xiii	  
determined, in order to provide evidence on the clinical significance of warfarin-
antibiotic interactions in older adults. 
 In the first project a cross-sectional analysis of the prescription and resident files 
from the 2004 National Nursing Home Survey was done to determine the prevalence of 
AF and rates of use of warfarin and other anti-platelet agents, such as aspirin and 
clopidogrel. A multiple logistic regression model was used to determine factors 
associated with warfarin use. In this sample of older NH residents, 13% of residents had a 
diagnosis of AF, with indications for warfarin use and no contraindications to warfarin. 
From these patients, 30% received anticoagulant therapy with warfarin and 23% of the 
remaining patients received either aspirin or clopidogrel, suggesting that more than 50% 
of residents with AF did not receive any form of anticoagulant therapy. Non-white race, 
history of bleeding, and use of anti-platelet medications were associated with reduced 
odds of receiving warfarin.  
 The second project was a retrospective medical record review of older patients 
from an outpatient anticoagulation clinic at a Veterans Affairs medical center. Results of 
the repeated measures ANOVA suggested a significant increase in post-antibiotic INR 
values with fluoroquinolones, azithromycin and amoxicillin. In addition, the percentage 
of patients with warfarin dose adjustments was significantly greater with 
fluoroquinolones and azithromycin as compared to cephalexin. No bleeding events were 
reported for any of these patients.  
In conclusion, the results of the projects suggest that there is underuse of warfarin 
in NH settings. Furthermore, antibiotics may be safely prescribed with warfarin in older 
adults as long as the INR is monitored closely.
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CHAPTER 1  
Introduction 
I. Medication-Related Problems in Older Adults 
Older adults are the largest consumers of medications, such that more than half the 
community-dwelling older adults in the US are prescribed 5 or more medications, over-
the-counter medications or dietary supplements.(1) Nursing home residents are 
prescribed an average of 7-8 medications.(2) Due to this high use of medications, older 
adults have the greatest risk of a medication-related problem (MRP).(1) A medication-
related problem may be defined as “an event or situation involving drug therapy that 
negatively interferes with a patient’s health”.(3) The average number of MRPs in older 
adults ranges from 2 to 3,(4) and these are generally more severe in older adults.(5) 
Aging increases the risk for MRPs since older adults become more sensitive to 
medications and may experience adverse drug reactions or increased side effects for 
several reasons. These reasons include- increased risk of chronic illnesses during which 
the body may metabolize or respond to drugs differently, multiple medications, complex 
dosing schedules, age-related physiological changes and higher likelihood of receiving 
un-coordinated care.(6) The high healthcare cost associated with MRPs may represent a 
serious economic problem. It has been estimated that for every dollar spent on drugs in 
nursing facilities, $1.33 in healthcare resources are consumed in the treatment of 
medication-related morbidity and mortality.(7) The total cost of MRPs is approximately 
$85 billion annually.(5) MRPs are commonly classified into eight general categories as 
shown in table 1.(3)  
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The research presented in this dissertation mainly focuses on two MRPs in older adults, 
i.e. untreated indication and drug-drug interactions, and specifically related to the high-
risk drug warfarin. Rates of untreated indication or underuse of beneficial medications in 
older adults have been reported to be present in around 62-64% of older adults.(8, 9) 
Similarly, drug-drug interactions are highly prevalent in older adults, such that 
approximately 2.2 million older adults were found to be at a risk of a major potential 
drug-drug interaction in a national cross-sectional study.(1) Nearly, half of these involved 
the use of warfarin or the anti-platelet agent, aspirin.  
 
Interestingly, many MRPs are believed to be predictable and therefore preventable. In a 
study that assessed the incidence and preventability of adverse drug events in ambulatory 
patients aged 65 years and above, of the 1523 adverse drug events that were reported, 
27.6% (421) were judged preventable.(10) On December 9, 2008, the American Society 
of Consultant Pharmacists (ASCP) submitted a written report to the transition team of 
then President-Elect Barack Obama, to highlight the issues surrounding MRPs in older 
adults along with some suggestions for reducing the prevalence of these problems.(11) 
Thus this health care issue has received national importance. Furthermore, by 2030 the 
population of Americans aged 65 years or older is expected to double, given the longer 
life expectancy and aging baby boomers.(12) Thus MRPs in the aging population may 
have an even greater impact on health care costs as the population is expected to reach 71 
million by 2030, which would roughly represent 20% of the US population. 
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Table 1: Categories of medication-related problems in older adults (3) 
Type of MRP Definition 
1. Untreated Indication Patient requires drug therapy but is not receiving medication 
for that indication 
2. Improper Drug 
Selection 
Patient requires drug therapy but is taking the wrong 
medication 
3. Subtherapeutic 
Dosage 
Patient is being treated with an inadequate dose of the correct 
medication 
4. Failure to Receive 
Drugs 
Patient has a medical problem that is the result of not receiving 
a drug 
5. Overdosage Patient is being treated with too much of the correct drug 
6. Inverse Drug 
Reaction 
Patient has medical problem that is the result of an unintended 
and detrimental adverse drug effect 
7. Drug Interaction Patient has medical problem that is the result of a drug-drug, 
drug-food, or drug-laboratory interaction 
8. Drug Use Without 
Indication 
Patient is taking a drug without a valid medical reason 
 
II. Use of High-Risk Medications in Older Adults 
Although warfarin is a frequently prescribed medication in the older population, it is also 
considered to be a high-risk medication.(13) Warfarin has been included in the list of 
high-alert medications developed by the Institute for Safe Medication Practices 
(ISMP).(14) This list was developed based on error reports submitted to ISMP’s national 
reporting program, harmful error reports from the literature and inputs from practitioners 
and safety experts. An increased risk of adverse events due to warfarin has also been 
supported by previous research. National estimates of emergency department (ED) visits 
among US patients aged 65 years and older found that of 177,504 ED visits for adverse 
drug events in 2004-2005, only 3.6% of them visits were for medications considered to 
be potentially inappropriate according to the Beers criteria.(15) Instead 33% of visits 
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were due to adverse events from 3 other medications, i.e. warfarin (17.3%), insulin 
(13.0%) and digoxin (3.2%). However, warfarin, insulin and digoxin are critical 
medications that should not be labeled as ‘inappropriate’ due to the high rates of ED 
visits. Instead, greater efforts may be required for improving the quality of prescribing 
and monitoring for patients on these high-risk medications. According to Budnitz et al, 
“because of the high risk for adverse events and the common outpatient use of warfarin, 
insulin and digoxin, even small improvements in the use of these medications may have 
greater potential for reducing the burden of serious adverse drug events among older 
Americans, as measured by ED visits, than do large reductions in the prescription of 
lower-risk medications, such as those considered to be potentially inappropriate by the 
Beers criteria.”(15) Furthermore, warfarin is prescribed frequently for older adults. In a 
cross-sectional, nationally representative probability sample of community-residing 
individuals aged 57-85 years, it was found that cardiovascular agents were the most 
commonly used class of prescription medications and this included anticoagulants such 
as warfarin.(1) 
 
A. Warfarin Pharmacotherapy 
Anticoagulation therapy with coumarins or vitamin K antagonists, such as warfarin, is 
recommended for the prevention and treatment of thromboembolic complications in 
patients with atrial fibrillation (AF), venous thromboembolism (VTE), and acute 
coronary syndromes and after invasive cardiac procedures.(16-18) It exhibits its 
anticoagulant effect by interfering with the γ-carboxylation of vitamin-K dependent 
coagulation factors II, VII, IX, and X, by preventing the cyclic interconversion of vitamin 
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K and its 2,3 epoxide (vitamin K epoxide), as shown in figure 1.(19) Warfarin is a 
racemic mixture of two optically active isomers, the R and S enantiomers, from which S-
warfarin is 2.7-3.8 times more potent than R-warfarin and is metabolized by the CYP2C9 
enzyme, whereas R-warfarin is metabolized by CYP1A2 and 3A4.(19) Warfarin is 
highly-water soluble and reaches maximal blood concentrations about 90 minutes after 
oral administration due to its high bioavailability.(19) 
 
Although warfarin has been the mainstay of oral anticoagulant therapy for over 60 years, 
it remains a challenge to use in clinical practice since several factors may complicate 
warfarin therapy. It is a drug with a narrow therapeutic index and exhibits considerable 
variability in dose response; thus, maintaining therapeutic levels of warfarin is 
challenging.(19) It is due to these reasons that patients taking warfarin are required to 
have their international normalized ratio (INR) monitored frequently. INR is a standard 
used for assessing the clotting tendency of blood in patients receiving anticoagulant 
therapy. The recommended INR monitoring period is every 4 weeks; however, this may 
change depending on patient-related factors, number of medications or when changes are 
made to the patient’s diet or drug regimen.(19) According to the American Geriatrics 
Society (AGS) guidelines for use of warfarin in older adults, the recommended INR 
range is 2.0-3.0 for prevention and treatment of venous thrombosis and 
thromboembolism, prevention of stroke in patients with non-valvular atrial fibrillation 
and/or acute myocardial infarction, and in patients with valvular heart disease.(20) The 
target INR range may be higher in patients who suffer recurrent systemic embolism 
despite adequate oral anticoagulant therapy (2.5-3.5; target INR=3.0). 
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Figure 1: Mechanism by which warfarin inhibits the vitamin-K dependent synthesis 
of biologically active forms of essential clotting factors, II, VII, IX and X.(19) 
 
 
(Figure excerpted from Ansell J, et al. Chest 2008; 133 (6 Suppl):160S-98S) 
 
B. Warfarin-Related Adverse Anticoagulation Outcomes  
The most common adverse outcome caused by warfarin is a bleeding event. The rates of 
fatal or major bleeding have been determined to be about 1.35 per 100 patient years, and 
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the rates of intracranial hemorrhage (ICH) was 0.4 per 100 patient-years.(21) Rates of 
major hemorrhage in patients treated with warfarin in routine clinical practice have been 
reported to range from 1.7-3.4%.(21) Some factors that directly govern the risk of a 
bleeding event during warfarin therapy include, the intensity of anticoagulation, patient 
characteristics such as age, concomitant use of drugs that may interfere with hemostasis 
and the length of therapy.(21) As shown in figure 2, the ‘ideal’ balance between 
prevention of ischemic stroke and avoidance of hemorrhagic complication is achieved at 
an INR from 2.0-3.0. According to the results of a meta-analysis, the risk for hemorrhage 
and thromboemboli was minimized when the patients’ INR remained within 2.0-3.0, 
whereas, the risk of bleeding increased significantly for INR values within 5.0-9.0.(22) It 
is well established that the risk of hemorrhage is the highest during the first 3 months of 
warfarin therapy.(23) 
 
The definition of a bleeding outcome may vary across studies. Some studies define 
bleeding as being minor, major or life threatening. Minor bleeds are those that are 
generally reported to the physician, but do not require additional testing, referrals or 
visits. Bleeding may be defined as major if it is intracranial or retroperitoneal, if it 
directly leads to death or if it results in hospitalization or transfusion.(21) Major bleeding 
may also be defined as life threatening bleeding in some cases. Although very rare, 
intracranial hemorrhage is the most feared complication during warfarin therapy, since 
most patients do not completely recover. Several different strategies are available for the 
management of supratherapeutic INR, i.e. INR > 4.0, or a bleeding event. Depending 
upon the INR or severity of the bleed, warfarin dose may either be lowered or omitted. 
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The patient may be administered vitamin K or more than one warfarin dose may be 
withheld. In the case of significant bleeding, the patient may be given a vitamin K 
infusion, supplemented with fresh frozen plasma, prothrombin complex concentrate or 
recombinant factor VIIa.(19, 24) 
 
An association of increasing age with increased risk of serious bleeding has been 
demonstrated in a recent meta-analysis (adjusted hazard ratio per decade increase, 1.16; 
95% CI, 1.47-1.77).(25) Since hemorrhagic events are the major complications of 
warfarin therapy, such events may limit warfarin use in older adults, especially frail older 
adults.(21, 23) Under-treatment of high-risk atrial fibrillation patients with warfarin 
therapy in clinical practice has been reported consistently in the past across all patient 
populations.(26) It is possible that the rates of under-treatment with warfarin may be even 
higher for older adults, especially for frail nursing home residents with atrial fibrillation, 
for whom the fear of bleeding events may be higher. Fear of bleeding complications is 
often cited as the reason for not adequately prescribing warfarin and the perception of 
stroke and bleeding risk has shown considerable variation among physicians.(27) 
Physicians are often more likely to overestimate the reported risks of major bleeds with 
warfarin, which may further result in under-treatment with anticoagulant therapy for 
patients with atrial fibrillation.(28) Due to this possible association between fear of 
bleeding complications in older adults and under-treatment with warfarin, it is important 
to determine the rates of warfarin use in older adults, especially frail nursing home 
residents in whom anticoagulation rates may not have been adequately studied 
previously.  
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Figure 2: Adjusted odds ratio for ischemic stroke and intracranial bleeding in 
relation to intensity of anticoagulation as measured by the international normalized 
ratio (16) 
 
(Figure excerpted from Fuster V, et al. Europace. 2006; 8(9):651-745) 
 
C. Warfarin-Drug Interactions 
ASCP includes drug-drug interactions as one of the top 5 medication-related problems 
commonly seen in older adults. (29) Many medications undergo pharmacokinetic or 
pharmacodynamic interactions with warfarin,(30) and warfarin-drug interactions have 
been ranked at number 3 in the list of top 30 adverse events reported for warfarin in the 
FDA’s Adverse Events Reporting system for the period from June 2003 to July 2006.(31) 
These top 30 adverse events were either indicative of, or associated with bleeding events. 
In addition, out of the top 10 dangerous drug interactions in nursing home residents, 5 of 
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the interactions involve warfarin, and 3 of these involve warfarin-antibiotic combinations. 
The second, third and fourth most dangerous drug interactions on this list involve 
warfarin with sulfa drugs, macrolides and fluoroquinolones respectively. This list was 
developed as one of the initiatives of the Multidisciplinary Medication Management 
Program.(32) Furthermore, the most recent systematic review on warfarin-drug 
interactions, recommends exercising caution while prescribing antibiotics to warfarin 
patients, since they may cause a change in the patient’s hematological response to 
warfarin.(30) Among the various antibiotic classes, fluoroquinolones, macrolides, 
tetracyclines and penicillins have been listed in the review article.  
 
Studies have shown that warfarin and antibiotics are commonly co-prescribed in older 
adults. For example, in a study of 256 patients discharged on warfarin, 54% received a 
potentially interacting medication, from which 67% of the prescriptions were for 
potentially interacting antibiotics.(33) In another study done in the Netherlands, almost 
39% of all users of coumarin anticoagulants were co-prescribed an anti-bacterial drug 
that was considered to be potentially interacting with warfarin.(34) Potential warfarin 
interacting antibacterial agents, such as sulphonamides, quinolones and macrolides, were 
also found to be the most widely co-prescribed class of drugs with warfarin, in a study 
done in Scotland.(35) An interesting finding of this study was that the rate of prescribing 
of macrolides in warfarin patients was lower than the rate for non-warfarin patients. This 
may suggest an increased awareness among physicians regarding the risk of this potential 
interaction. However, no study done in the United States has shown this difference in 
prescribing patterns between users and non-users of warfarin. Adverse outcomes 
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associated with warfarin use have also been demonstrated previously. Of all the patients 
that were admitted to an emergency department, 11% were admitted due to a warfarin 
drug interaction.(36, 37) Antibiotics also led to over-anticoagulation in hospitalized 
patients receiving oral anticoagulants, such that 8 of the 13 patients that experienced an 
increase in INR>5.0 had recently started therapy with antibiotics, antifungals or 
amiodarone.(38) Fluoroquinolones are a widely used class of antibiotics. A study that 
assessed the trends of antibacterial use in the United States from 2002 to 2006 concluded 
that out of all classes of antibiotics, fluoroquinolones were the most commonly used.(39) 
However, the clinical significance of warfarin-fluoroquinolone interactions is not 
clear,(40) suggesting that there is a need for further research on warfarin-antibiotic 
interactions. 
D. Summary 
This chapter gave an overview of medication-related problems in older adults with a 
focus on two types of MRPs, that is, untreated indication and drug-drug interactions. 
Certain issues with the use of warfarin therapy in older adults were also highlighted. The 
next chapter provides a detailed literature review of underuse of warfarin in nursing home 
settings and the available clinical evidence for warfarin-antibiotic interactions. It also 
provides a literature review of the effect of age on warfarin-fluoroquinolone interactions. 
The next section will provide some gaps in the literature as they relate to underuse of 
warfarin and warfarin-antibiotic interactions in older adults and the significance of 
conducting this research. 
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CHAPTER 2  
Literature Review 
 
I. Warfarin Use in Nursing Home Residents 
The purpose of this section is to review the available literature to determine the 
prevalence of warfarin use in nursing home (NH) residents. This would help to develop a 
better understanding of the use of this ‘high-risk’ medication in NH residents who 
generally tend to be frailer than community-dwelling older adults and are using multiple 
medications for multiple co-morbid conditions. The literature was also searched to 
identify the factors associated with use of warfarin in NH residents.  
 
A. Review of the Literature: 
Overall three studies have determined the prevalence of warfarin use specifically in NH 
residents. In the study by McCormick et al., the medical records of all residents from a 
convenience sample of 21 community-based long-term care facilities were reviewed to 
determine whether they had a diagnosis for atrial fibrillation (AF).(1) From a total of 
2587 records, 429 (17%) residents had a diagnosis for AF. Of these 429 patients with AF, 
180 (42%) were prescribed warfarin and from the 83 ‘ideal’ candidates with AF and no 
contraindications to warfarin use, only 44 (53%) received warfarin. Similarly, in another 
study the medical records of patients residing in 30 long-term care facilities were 
reviewed to determine the prevalence of AF and the proportion of patients receiving 
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anticoagulation therapy.(2) A total of 5500 residents were studied from which 413 (7.5%) 
were residents with a diagnosis for AF. Of these 413 subjects with AF, 130 (32%) 
received a treatment with warfarin. One of the earliest studies to have documented an 
underuse of warfarin in nursing home residents showed that only 17 (20%) of 85 patients 
with AF received anticoagulation therapy with warfarin.(3) A summary of these studies 
has been presented in table 1. Furthermore, a recent study evaluated the treatments 
received by patients for stroke prevention using data from the Minimum Data Set 
(MDS).(4) From a total of 14,469 patients identified with a previous stroke event, 48% 
received warfarin or any kind of antiplatelet medication such as clopidogrel, aspirin, 
ticlopidine or dipyridamole. The biggest limitation of this study is that MDS does not 
differentiate between ischemic and hemorrhagic stroke. Since anticoagulant or 
antiplatelet therapy is not recommended for patients who have had a hemorrhagic stroke, 
the rates of underuse may have been over-estimated. Thus while determining the 
prevalence of warfarin use in patients with AF, it is beneficial to identify a group of 
patients with AF who do not have any contraindications to anticoagulant or antiplatelet 
therapy.  
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Table 1: Summary of studies documenting underuse of warfarin in 
nursing home residents with atrial fibrillation 
 
Reference Study 
Setting 
Total no. of 
Residents 
(N) 
N (%) of 
Residents 
with AF  
N (%) 
Treated 
with 
Warfarin 
Factors 
Associated with 
Warfarin Use 
McCormick 
(2001)(1)  
 
21 LTC 
facilities 
2587 429 (17%) 180 (42%) Number of 
bleeding risk 
factors 
 
Gurwitz 
(1997)(2)  
 
30 LTC 
facilities 
5500 413 (7.5%) 130 (32%) Age ≥ 85 years, 
history of stroke, 
diagnosis of 
dementia 
 
Lackner 
(1995)(3)  
5 
Nursing 
Homes 
902 85 (9.4%) 17 (20%) - 
LTC = Long-term care 
 
B. Significance  
Based on a review of the literature, studies have consistently reported an underuse of 
warfarin in long-term care facilities with the rates of underuse ranging from 50-70%. 
However, most of these studies were done more than 10 years ago. Newer anti-platelet 
medications, such as clopidogrel have become available for secondary stroke prevention 
and are increasingly being used for patients in whom warfarin is contraindicated. Other 
antiplatelet medications such as ticlopidine are not recommended for use in older adults 
anymore. While previous studies have included a sample of residents from many long-
term care facilities, none of them included a nationally representative sample of long-
term care residents. An estimation of national rates of NH residents with AF and those 
	   22	  
receiving anticoagulant or antiplatelet therapy would help to understand the current 
practices that are adopted for stroke prevention in NH settings and lack thereof. 
Furthermore, identifying factors that are associated with warfarin use may help to target 
these factors to develop future interventions to improve anticoagulant therapy in older 
adults.  
 
II. Warfarin-Antibiotic Interactions 
The purpose of this section is to review the published literature on warfarin-antibiotic 
interactions, separately for fluoroquinolones, macrolides and penicillins, in order to 
understand and evaluate the current state of knowledge of the clinical significance of 
warfarin-antibiotic interactions. MEDLINE, TOXLINE, International Pharmaceutical 
Abstracts (IPA), the FDA website and www.guideline.gov, were searched for relevant 
literature. The aim of the literature search was to identify studies that have assessed or 
reported any interaction between warfarin and quinolones. The search strategy used was 
(warfarin AND (quinolones OR ciprofloxacin OR levofloxacin OR moxifloxacin)). 
Gatifloxacin was not included because it has been removed from the US market. 
Similarly norfloxacin was not included due to its limited use. Articles were included if 
they were in English and were original research studies with data from human subjects. 
Relevant articles that showed up in the related search and in bibliographies of the 
retrieved articles were also included. The search yielded a total of 107 articles from 
which 35 were reviews. From the remaining 72 articles, 35 were found to be relevant. 
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A. Warfarin-Fluoroquinolones Interaction 
Most of the evidence for warfarin-fluoroquinolone interactions comes from case reports 
or case series and these reports have been summarized in Tables 2, 3, and 4 for warfarin-
ciprofloxacin, levofloxacin and moxifloxacin interactions respectively. As shown in 
Table 2, seven case reports or case series, reporting warfarin-ciprofloxacin interactions 
have been published.(5-11) These included a total of 9 patients, from which 5 patients 
were 70 years or above. There was a marked prolongation of prothrombin time in these 
patients, with 2 patients experiencing hematuria or hematemesis.  
 
Four case series or case reports of a warfarin-levofloxacin interaction, involving a total of 
11 patients, have been published and have been summarized in Table 3.(12-15) From 
these 11 patients, 8 patients were 65 years and above. All 11 patients experienced a 
substantial increase in INR values above the therapeutic range. This elevation in INR 
resulted in hemopericardium in 2 patients, retroperitoneal bleeding with psoas muscle 
bleeding in 1 patient and a case of minor bleeding in another patient. Some strategies that 
were used to manage this interaction were warfarin dose reduction, withholding warfarin 
therapy and administration of vitamin K and fresh frozen plasma (FFP). There have been 
12 reported cases of a warfarin-moxifloxacin interaction as shown in Table 4, and 
bleeding events were reported for 2 of these cases.(16, 17) 
 
Since most of the evidence for clinical significance of warfarin-fluoroquinolone 
interactions come from case reports they may represent a publication bias and there is 
minimal control on confounding factors such as diet, nutritional status, and concomitant 
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medications in case reports. For example, the pre-antibiotic INR was not reported in 
some of the case reports.(11, 15) If the patient’s INR was not stable before the antibiotic 
was started, the INR may continue to fluctuate as compared to a patient with stable INR. 
The increase in INR may then be incorrectly attributed to the antibiotic for such cases. In 
one of the case series, a patient had a fluctuating INR even before moxifloxacin was 
started. This fluctuation may have been due to initiation of heparin therapy. Warfarin 
therapy had already been discontinued for this patient who was not on concomitant 
warfarin-moxifloxacin therapy during INR elevation.(16) 
 
There have been 3 prospective studies to determine the interaction potential between 
warfarin and ciprofloxacin.(18-20) The first 2 studies showed that ciprofloxacin did not 
alter the pharmacokinetics (PK) or pharmacodynamics (PD) of warfarin and the third 
study showed that there was no increase in the patient’s INR. However, since these were 
PK/ PD studies they were done in healthy male volunteers and only a single dose of 
warfarin and/ or ciprofloxacin was administered to the patients. In addition, healthy 
volunteers without any infection are not representative of patients who are normally 
prescribed an antibiotic for an active infection. In the presence of certain infections such 
as pneumonia, there may be greater inhibition of hepatic enzyme activity,(21) in addition 
to suppression of vitamin K producing bacterial flora by the antibiotic in question. These 
factors may further interfere with warfarin metabolism and increase the anticoagulant 
activity of warfarin. Such effects may not be evident in PK/ PD studies.  
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Table 5 is a summary of retrospective and prospective studies that assessed warfarin-
levofloxacin interactions. From the 4 retrospective cohort studies that determined the 
mean change in INR after administration of levofloxacin to patients on stable warfarin 
therapy, 2 studies found a significant increase in mean INR change,(22, 23) whereas the 
other 2 did not find a significant change.(24, 25) One prospective study found no 
significant increase in INR with the addition of levofloxacin to warfarin therapy in 18 
patients with an active infection.(26) However, 9 of the 18 patients had a warfarin dose 
adjustment based on the first INR values obtained after start of levofloxacin. For these 
patients only the first INR value was used in the analysis, and this may have limited the 
ability to identify the effect of levofloxacin on INR values if the interaction occurred after 
this INR value had been recorded. 
 
The effect of warfarin-levofloxacin combination on the risk of bleeding has also been 
examined in 2 nested case-control studies.(21, 27) The outcome of interest was hospital 
admission due to hemorrhage, caused by a warfarin-levofloxacin interaction.(27) 
Cefuroxime was chosen as the comparator drug. Patients who were started on 
levofloxacin were not more likely to undergo hemorrhage (OR=1.21, 95% CI=0.84, 
2.01), unlike those on cefuroxime (OR=1.62, 95% CI= 1.28-2.26). In another similar 
nested-case control study assessing the risk of GI bleeding due to warfarin-antibiotic 
interactions, levofloxacin was not shown to be associated with an increased risk of 
bleeding.(21) Thus both these studies did not show an increase in the risk of clinically 
significant hemorrhagic outcomes. Finally, as of January 15, 2004, Health Canada 
received 57 reports of suspected coagulation disorders possibly caused by warfarin-
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fluoroquinolone interactions.(28) Health Canada is the department of the government of 
Canada that is responsible for national public health. From these, 10 cases involved an 
interaction with warfarin and ciprofloxacin, 13 involved gatifloxacin, 16 involved 
levofloxacin and12 were with moxifloxacin.  
 
Thus based on the literature review of warfarin-fluoroquinolone interactions, most of the 
evidence for an interaction comes from case series or case reports and prospective and 
retrospective studies suggest that this interaction may not be clinically significant. 
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Table 2: Warfarin-ciprofloxacin case reports 
Reference N Mean age 
(years) 
Mean INR 
Change 
Mean PT Change 
(sec) 
Bleeding Complications 
Ellis (2000)(5) 2 53 28 15.7 Bilateral subdural hematomas, intractable 
epistaxis 
 
Byrd (1999)(6) 1 77 3.17 9.1 Intracerebral bleed leading to death 
 
Kramer (1991)(7) 1 70 - 15.5 None 
 
 
Renzi (1991)(8) 1 48 - 50.4 None 
 
Jolson (1991)(9) 2 85 - 69 Hematuria 
 
Kamada 
(1990)(10) 
1 72 - 6.5 None 
 
 
Mott (1989)(11) 1 72 - - Hematemesis 
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Table 3: Warfarin- levofloxacin case reports 
Reference N Mean age 
(years) 
Mean INR 
Change 
Mean PT Change 
(sec) 
Bleeding Complications 
Vadlamudi 
(2007)(12) 
3 61 5.5 - Hemopericardium, cardiac tamponade, retropeitoneal 
hematoma, death 
 
Jones (2002)(13) 4 62 2.74 - Epistaxis (1 case) 
 
Ravnan 
(2001)(14) 
2 73 3.6 - None 
 
Gheno 
(2001)(15) 
2 77 - - None 
 
 
Table 4: Warfarin-moxifloxacin case reports 
Reference N Mean age (years) Mean INR Change Mean PT Change (sec) Bleeding Complications 
Yildiz (2008)(16) 
 
1 74 10 - Hematuria and diffuse ecchymosis 
Elbe (2005)(17) 
 
5 77 6.7 - Upper GI bleed (1 case) 
Arnold (2005)(29) 
 
3 67 3.5 - none 
O’Connor (2003)(30) 
 
3 80 - - none 
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Table 5: Summary of warfarin-levofloxacin interaction studies 
Reference N Mean 
age (yrs) 
Design Outcome Measure Comparator 
Drug 
Result 
Orfila (2009)(31)  
 
21 75 Retrospective 
cohort 
Mean change in INR None Significant increase in INR 
(p=0.001)* 
Mathews 
(2006)(24)  
54 78 Retrospective 
cohort 
Anticoagulation-related 
outcomes a 
Gatifloxacin No difference in median INR 
changes between levofloxacin 
and gatifloxacin 
Stroud (2005)(27)  - 79b Nested case-
control  
Hospital admission for 
hemorrhage (ICD-9 
codes) 
Cefuroxime No significant increase in 
hospital admission for 
hemorrhage (OR = 1.21; 95% CI 
= 0.84 – 2.01) 
McCall (2005)(25)  22 59.5 Retrospective 
cohort 
Mean change in INR Felodipine No difference in mean change in 
INR between levofloxacin and 
felodipine (p=0.65) 
Glasheen 
(2005)(32)  
27 69 Retrospective 
cohort 
Mean change in INR Terazosin  Significant difference in mean 
INR change between 
levofloxacin and terazosin 
(p<0.01)* 
Yamreudeewong 
(2003)(26)  
18 68 Prospective 
open-label 
Mean change in INR None No difference in mean INR 
change (p=0.419) 
a Anticoagulation-related outcomes = postfluoroquinolone INR > 4, > goal, ≥ 1 point above goal; INR change 0.5-0.99, 1-1.49, ≥ 1.5 
points; vitamin K administration; warfarin dose withheld, warfarin dose reduced, major and minor bleed, ER visits, hospital 
admissions, any intervention. 
b Mean age at the start of cohort = 79 years	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A. Warfarin-Macrolides Interaction 
As compared to erythromycin, azithromycin and clarithromycin are considered to be 
safer antibiotics to prescribe with warfarin.(33) However, most of the evidence comes 
from single case reports and case series and should thus be interpreted with caution, since 
they are likely to represent a publication bias. Several case series have reported an 
elevation in INR or prothrombin time (PT) when clarithromycin was administered 
concomitantly with warfarin.(34-38) Similarly, warfarin-azithromycin interactions have 
mainly been reported via case series, as shown in Table 6.(39-43) There have been only 
3 retrospective studies that have looked at the potential interaction between azithromycin 
and warfarin and these have been summarized in Table 7.(23, 33, 44) Two of these 
studies did not find any evidence for a significant interaction between warfarin and 
azithromycin.(32, 44) The sample size in these studies was very limited with the largest 
study having a sample size of only 52 patients and thus the power to detect a difference in 
the INR may have been low for most of them. 
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Table 6: Warfarin-azithromycin case reports 
Reference N Mean age (yrs) Mean INR Change Mean PT change (sec) Bleeding Complications 
Shrader 
(2004)(43)  
1 57 5.5 - None 
 
Williams 
(2003)(45)  
1 72 10.4 95.5  Large hematoma 
 
Foster 
(1999)(40)  
1 71 12.16 - Right upper quadrant hematoma 
 
Woldtvedt 
(1998)(39)  
1 53 Too high to 
quantify 
-   
(Maximum PT = 106) 
Coughing blood and blood streaked 
mucus 
 
Table 7: Summary of warfarin-azithromycin interaction studies 
Reference N Mean age 
(years) 
Design  Outcome 
Measure 
Comparator 
Drug 
Result 
Glasheen 
(2005)(23)  
32 72 Retrospective 
cohort 
Mean change 
in INR 
Terazosin  Significant difference in mean INR 
change between groups (p<0.05)* 
 
McCall 
(2004)(44)  
17 59 Retrospective chart 
review 
Mean change 
in INR 
Felodipine No difference in mean change between 
groups (p=0.74) 
 
Beckey 
(2000)(33)  
26 68.9  Retrospective chart 
review  
Mean change 
in INR 
Terazosin No difference in mean change in INR 
between groups (p=0.60) 	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C. Warfarin-Penicillins Interaction 
There have been very few case reports for warfarin-amoxicillin or warfarin-
amoxicillin/clavulanic acid interaction.(46, 47) One article reported an interaction 
between amoxicillin and acenocoumarol, a coumarin anticoagulant that is not used in the 
United States.(48) So far 3 studies have reported either hospitalization due to bleeding or 
INR ≥ 6 for amoxicillin/clavulanate for patients on other coumarin anticoagulants, such 
as acenocoumarol or phenprocoumon.(49-51) The only study to have assessed the risk of 
bleeding with amoxicillin for patients on warfarin was published recently.(52) This study 
did not find an association between risk of hemorrhage and use of warfarin-amoxicillin or 
warfarin-ampicillin combination. However, Micromedex lists warfarin-amoxicillin/ 
clavulanate interactions as being of ‘moderate’ severity and the review by Holbrook et al. 
list this as a ‘probable’ (class II) interaction.(53)  
 
D. Discussion  
The clinical evidence for an interaction between warfarin and fluoroquinolones, 
macrolides and penicillins in older adults is very limited and most of the evidence comes 
from case reports and case series or from poorly designed retrospective studies. There 
were several limitations of the studies that were reviewed in this section. The effect of 
increasing age on warfarin-antibiotic interactions was not considered in these studies. 
Due to the high prevalence of thromboembolic conditions with increasing age, older 
adults represent the highest users of warfarin therapy.(54) In addition, indications such as 
urinary tract infections and pneumonia, for which antibiotics are prescribed, are more 
prevalent in older adults.(55, 56) Thus adequate representation of older adults in 
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warfarin-antibiotic studies may be important. If older age plays an important role in the 
potentiation of the drug interactions, it is possible that under-representation of older 
adults in some of these studies may have resulted in findings that were not significant. 
Since studies conducted so far have included patients with variable age ranges, the 
potential for increased anticoagulation due to warfarin-antibiotic interactions in older 
patients remains inadequately studied.  
 
The active infection for which the antibiotic is prescribed may also be playing some role 
in intensifying the anticoagulant activity of warfarin. The activity of some CYP450 
enzymes may be reduced during an infection or inflammation, which may further reduce 
warfarin metabolism.(21) Due to the potential role of infection, it may be important to 
study warfarin-antibiotic interactions in patients who have an acute infection. However, 
across the 4 prospective trials, only 26% of the patients had an acute infection.(57) The 
advantage of the retrospective studies was that the subjects had an active infection. The 
study by Schellman et al. found evidence for the role of infection in causing an increase 
in the bleeding risk for patients on warfarin therapy. This study suggested that infection 
or its sequelae, such as fever or reduced vitamin K intake may be responsible for an 
increased risk of bleeding since the odds ratio (OR) for the ‘baseline’ risk of bleeding 
was already significantly elevated for the subjects before the start date of the 
antibiotic.(21) In addition to the indication for which the antibiotic is prescribed, several 
other confounding factors are also important to consider while studying warfarin 
interactions. Older adults often have multiple comorbidities and use multiple 
medications. The decline in renal function with age may also necessitate dose reduction 
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of renally eliminated antibiotics such as quinolones. Prospective studies or 
pharmacokinetic and pharmacodynamic studies are limited in studying the effect of these 
confounders. Thus in addition to studying this interaction in older adults, and in patients 
with an infection, there is some value in studying this interaction in clinical settings, 
which include patients with multiple disease conditions.  
 
The lack of a control drug or choice of a poor control drug was a common limitation seen 
in several studies. Retrospective studies of warfarin-levofloxacin interactions have used 
cefuroxime, felodipine and terazosin as the comparator drugs,(23, 25, 27) and studies of 
warfarin-azithromycin interaction have used felodipine and terazosin.(33, 44) While 
felodipine and terazosin have indications for use that are very different from antibiotics, 
the antibiotic cefuroxime was found to significantly increase hospital admissions due to 
hemorrhage in patients on stable warfarin therapy. Suitable choice of a control drug is a 
challenge, since many antibiotics are implicated to potentially interact with warfarin. Yet 
it may be important to assess the interaction effect using a control drug that is an 
antibiotic. This is because by comparing a warfarin user who is prescribed an antibiotic to 
a warfarin user who is prescribed a different antibiotic, it is possible to study subjects 
whose baseline bleeding risks are more comparable. This would help to reduce some bias 
due to confounding by indication and also help to distinguish between the effect of a drug 
interaction and the effect of infection or its sequelae, such as fever and reduced vitamin K 
levels. Although it is a challenge to find a suitable control drug to study warfarin-
interactions, the importance of using a comparator drug cannot be underestimated.  
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Some studies did not use clinically meaningful outcomes such as bleeding events, 
hospital admissions, warfarin dose adjustments, or administration of vitamin K. Only 
mean change in INR before and after starting the antibiotic was assessed. Although, 
increase in INR is an important outcome since a supratherapeutic INR would increase the 
risk of a bleeding event, the use of secondary outcomes of over-anticoagulation or 
bleeding events may increase our understanding of the clinical significance of these drug 
interactions.  
 
E. Conclusion 
The most recent review that evaluated the possibility of increased anticoagulation due to 
warfarin-fluoroquinolone interactions concluded, “There are no consistent data to support 
the claim of an increased anticoagulation response in patients receiving warfarin and any 
of the three commonly prescribed fluoroquinolones”.(57) However, most of the studies 
included in this review had varied age ranges and may not adequately represent the older 
adult population. The prospective trials of concomitant administration of levofloxacin 
and ciprofloxacin in patients on warfarin did not demonstrate an increased 
anticoagulation response.(19, 20, 26) Meanwhile, the retrospective studies showed either 
significant increased elevation in INR,(23-25, 31) or significantly increased risk of 
hemorrhage.(27) However, these studies were not specifically done in older adults. Only 
3 studies of warfarin-levofloxacin were done in older adults from which 2 showed 
evidence of an interaction,(24, 27) and 1 failed to show significant bleeding outcomes 
due to this interaction.(21) An outcome of a bleeding event always has to be considered 
in light of the patient care environment. If the dose is lowered due to an elevated INR, 
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then a bleeding event was avoided. Thus even though a warfarin-quinolone interaction 
may not result in adverse bleeding outcomes for all patients, over-anticoagulation caused 
by elevations in INR may still be an important outcome to consider for older patients due 
to the risks of hemorrhagic events associated with elevated INR.(58)  
 
F. Significance 
Changes in tissue distribution, declining renal function and presence of chronic disease 
states that require long-term drug therapy may put older adults at a higher risk for drug-
drug interactions that may result in significant ADEs. Although warfarin clearance is not 
affected by a decline in renal function, serum levels of potentially interacting drugs, such 
as ciprofloxacin and levofloxacin may increase, thus enhancing the likelihood of a 
clinically significant interaction. Yet studies on warfarin-antibiotic interactions have not 
examined the effect of increasing age on the risk of over-anticoagulation or bleeding 
outcomes. Awareness of the differences in PK and PD profiles of warfarin and 
quinolones and the potential risk of this interaction in older adults may guide clinicians in 
making appropriate treatment choices while co-prescribing antibiotics with warfarin. 
Older adults are taking multiple medications for multiple co-morbid conditions. They are 
physically frailer, have poor nutritional status and due to their high risk of falls, the risk 
of bleeding events may be higher. 
 
The levels of warfarin monitoring required for vulnerable older adults may be higher due 
to increased sensitivity to warfarin effects. Potential warfarin antibiotic interactions may 
further complicate the clinical management of warfarin therapy in older adults. 
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Physicians managing an older patient’s warfarin therapy may sometimes be unaware of 
the co-prescription of antibiotics with warfarin due to the short course of therapy with 
antibiotics. Furthermore, it is possible that the risk of a warfarin-antibiotic interaction 
may be higher in older adults with multiple co-morbid conditions or for those taking 
multiple medications. In spite of the risks associated with warfarin use and the frequency 
with which it is prescribed in older adults, there are few precise estimates of the outcomes 
associated with co-prescribing potentially interacting medications such as antibiotics with 
warfarin. Thus the evidence base underlying the risk of warfarin-antibiotic interactions in 
older adults is weak and there is room for further research to better understand this risk.  
 
The next section is a literature review to determine the effect of increasing age on 
warfarin-antibiotic interactions in older adults. The literature has been reviewed to 
describe general pharmacokinetic and pharmacodynamic changes that occur in older 
adults and the effect of increasing age on the pharmacodynamics of warfarin and on the 
pharmacokinetics of fluoroquinolones. Fluoroquinolones were chosen as the class of 
antibiotics to review in detail because age-related changes in pharmacokinetics of 
fluoroquinolones have been documented more often than the other antibiotics. This 
section also provides an understanding of how these factors may play a combined role in 
potentiating the risk of warfarin-antibiotic interactions in older adults. Two cases have 
been presented as examples in order to provide a real clinical scenario.  
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III. Potential Effect of Age on Warfarin-Fluoroquinolones 
Interactions 
Several medications may undergo a pharmacokinetic (PK) or pharmacodynamic (PD) 
interaction with warfarin, thus increasing the risk of a bleeding event. Fluoroquinolones 
are a widely used class of antibiotics in older adults and reports of an interaction between 
warfarin and fluoroquinolones have been conflicting and inconsistent. The risk of an 
interaction may be higher in older adults due to age-related physiologic changes that may 
result in altered PD response for warfarin and altered PK of fluoroquinolone antibiotics. 
A search for relevant articles using PubMed (1975-2011) and International 
Pharmaceutical abstracts (1975-2011) was conducted in order to review articles on age-
related PK and PD changes in fluoroquinolones and warfarin and the possible           
mechanisms of the interaction. Case reports and evidence from other coumarin 
anticoagulants were excluded. The literature suggests an age-related increase in 
sensitivity to warfarin response and an age-related reduction in clearance of 
fluoroquinolones, due to declining renal function in older adults. The mechanism of 
warfarin-fluoroquinolone interactions has not been fully elucidated but higher drug 
exposure of warfarin and fluoroquinolones due to PK-PD changes may potentiate this 
interaction in older adults. Reports of warfarin-fluoroquinolone drug interaction studies 
in older adults are limited thus highlighting the need for studies that examine the effect of 
increasing age on the risk of over-anticoagulation or bleeding outcomes due to warfarin-
fluoroquinolone interactions. This would lead to a better understanding of the 
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contribution of age-related PK-PD changes to this interaction. Finally, this may aid 
clinicians in making suitable treatment decisions while co-prescribing antibiotics with 
warfarin and may assist healthcare providers in anticoagulation clinics to better manage 
this potential drug interaction in older patients. 
 
A. Case Presentations 
A 72-year-old white male with atrial fibrillation was diagnosed with bronchitis. He was 
on stable warfarin therapy with a target INR range from 2.0 – 3.0. His weekly warfarin 
dose was 82.5mg and he was prescribed moxifloxacin 400 mg daily for 10 days to treat 
his bronchitis. In the one month prior to initiation of moxifloxacin his INR ranged 
between 2.0 and 2.4. However, following commencement of moxifloxacin his INR 
peaked to 6.5. His warfarin dose was withheld for 3 days and a large bruise was observed 
on patient’s arm. A review of other concomitant medications revealed that moxifloxacin 
was the only potentially interacting medication that the patient was prescribed, suggesting 
that it may have caused the elevation in INR in this older patient. 
 
An 83-year-old white male with a history of deep vein thrombosis and pulmonary 
embolism was on stable warfarin therapy with a target INR range from 2.0 – 3.0. His 
weekly warfarin dose was 10 mg. He was prescribed levofloxacin 500mg daily for 7 days 
for pneumonia. Prior to initiation of the antibiotic his INR of 2.6 was within his target 
range. However, on day 5 of levofloxacin therapy his INR rose to 8.0. Following this 
elevation his warfarin dose was withheld for 3 days and his INR was rechecked before 
initiating warfarin therapy. An elevation in INR in this older patient may be caused as a 
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result of a drug interaction between warfarin and levofloxacin, since the patient was not 
prescribed any other potentially interacting medications with warfarin. 
 
B. Introduction 
Warfarin is the most widely used oral anticoagulant and its use is higher in older adults 
due to increased prevalence of atrial fibrillation and other thrombotic disorders with 
advancing age.(54) In an analysis of national estimates of emergency department (ED) 
visits for adverse drug events in patients aged 65 years or older, 17% of all visits were 
from adverse drug events (ADEs) caused by warfarin, such that warfarin accounted for 
the highest rates of ED visits in this older adult population.(59) Ciprofloxacin, 
levofloxacin and moxifloxacin are the most widely used fluoroquinolone antibiotics in 
older adults.(60) Due to their potential to increase the anticoagulant activity of warfarin, 
co-prescription of quinolones with warfarin may cause a drug-drug interaction.(61) 
However, the clinical significance of warfarin-quinolone drug interactions has been 
questioned and the reports have been conflicting.(57) Yet warfarin-quinolones 
interactions were ranked as the fourth most dangerous drug interactions in a list of the top 
10 dangerous drug interactions in nursing home residents. This list was developed as an 
initiative of the Multidisciplinary Medication Management Project.(62) 
 
Since warfarin and antibiotics such as quinolones are commonly implicated for resulting 
in ADEs and due to the high rate of concurrent use of these medications in older 
adults,(63) it is important to understand if there exists a potential for a clinically 
significant drug-drug interaction in older adults. Increasing age is associated with several 
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pharmacokinetic (PK) and pharmacodynamic (PD) changes that may affect drug 
exposure in the older patient. A majority of the drug-drug interactions that affect older 
adults involve both PK and PD mechanisms. Thus the associated PK and PD changes in 
older adults may increase the potential of occurrence of an adverse event resulting from a 
drug-drug interaction. In addition, the adverse consequences of the drug-drug interaction 
may be more severe in older adults, especially frail older patients, since their physiologic 
reserve is already diminished. This review describes general pharmacokinetic and 
pharmacodynamic changes that occur in older adults, the effect of increasing age on the 
pharmacodynamics of warfarin, pharmacokinetic changes for fluoroquinolones with 
increasing age and how these factors may play a combined role in the mechanism of 
warfarin-quinolone interactions and potentially increase the risk of this interaction in 
older adults.  
 
C. Method 
The databases searched included PubMed and International Pharmaceutical Abstracts 
from the period, January 1975 to June 2011, using key words aged, frail elderly, 
pharmacokinetics, pharmacodynamics, warfarin, fluoroquinolones, quinolones, drug 
interactions and hemorrhage. Only English-language articles were included. Clinical 
trials and prospective and retrospective observational studies were included. Case reports 
and case series were excluded. Studies with a focus on other oral anticoagulants, such as 
phenprocoumon and acenocoumarol, were excluded from the review. Bibliographies of 
included articles were manually searched for additional studies that may be relevant.  
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D. General Pharmacokinetic and Pharmacodynamic Changes with Aging  
For most drugs absorption is not significantly altered with aging.(64) Aging is associated 
with a decrease in the total body water as a proportion of body weight, which results in a 
reduction of the volume of distribution of water-soluble medications; thus increasing 
their serum concentrations in the older patient. With an increase in total body fat with 
aging, lipid soluble drugs have a larger volume of distribution and tend to remain in the 
body for longer periods. However, protein binding of drugs is not significantly affected 
by aging.(65) Liver oxidative metabolism of drugs is often reduced in older patients, 
mainly due to reduced blood flow to the liver (~20-50%) and reduced liver size (~20-
30%).(64) The CYP450 enzyme system is responsible for the metabolism of warfarin and 
some fluoroquinolones, and intrinsic activity (oxidative metabolism) for this enzyme 
system is believed to be lower in older adults, compared to young adults.(66) 
Furthermore, renal function declines with age, thus necessitating dose reduction of 
certain renally eliminated medications in older patients. The Cockcroft-Gault equation is 
used to dose medications in older patients based on their creatinine clearance. However, 
this equation may overestimate renal function for frail patients, since their muscle mass is 
markedly decreased.(64) 
 
There is a lack of general understanding of pharmacodynamic changes in aging since 
these changes have not been well studied. The older patients’ response to drug therapy is 
generally affected by aging and disease-associated physiological changes. PD changes 
may occur due to changes in receptor affinity for medication, or post-receptor events such 
as altered signaling. In the case of warfarin, PD changes in older adults are mainly due to 
	   	   	  	  	  	  	  
	   43	  
altered homeostatic control mechanisms.(67) In some situations, PD changes may cause 
adverse drug events (ADEs) in older patients.     
 
E. Effect of Age on Pharmacodynamic Response to Warfarin 
Direct pharmacodynamic studies to determine the response to warfarin therapy are 
challenging as a result of a delayed therapeutic effect, which is mainly due to its 
mechanism of action. In addition, the effect of warfarin is sensitive to diet-associated 
changes in levels of vitamin K.(67) There is sufficient evidence from epidemiologic 
studies to suggest the association between older age and increased anticoagulant 
response, as a result of an increased sensitivity to warfarin with increasing age. Such an 
age-associated increase in sensitivity to warfarin has been demonstrated in an early 
pharmacodynamic study.(68) This was a prospective study of 4 older adults (age range 
62-89 years) and 4 young (age range 27-37 years) patients who were administered a 
single loading dose of warfarin. The anticoagulant response, as measured by vitamin K-
dependent prothrombin complex activity (PCA) using the Thrombotest procedure, was 
found to be greater in older patients as compared to younger patients. This was in spite of 
administering lower, weight-adjusted doses to the elderly. In addition, synthesis of 
vitamin-K dependent clotting factors was inhibited to a greater extent in older patients, at 
the same warfarin plasma concentrations as the younger patients. No age-related 
differences in warfarin pharmacokinetics were evident in this study. Thus, in addition to 
demonstrating the increased sensitivity to warfarin with age, this study demonstrated the 
mechanism of this altered sensitivity in older patients. The potential effect that coexisting 
clinical or medication factors may have on warfarin sensitivity could not be determined 
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in this study. In addition with increasing age these factors may further exaggerate 
warfarin response in older patients. 
 
An age-related increase in sensitivity to warfarin has also been demonstrated in a 
prospective cohort study of 530 patients from a university outpatient anticoagulation 
clinic, over a 10-year period.(69) Results from the multivariate linear regression model 
suggested that anticoagulant response to warfarin therapy, as determined by the dose-
adjusted mean PT ratio, was found to be exaggerated for older patients in the 60-69 and ≥ 
70 years age group as compared to those < 50 years (p<0.001). Furthermore, the mean 
daily warfarin dose declined substantially with increasing age (6.4 mg/day for patients < 
50 years vs. 3.6 mg/day for patients ≥ 70 years; p<0.001). However, this study did not 
demonstrate the mechanism for increase warfarin sensitivity in older adults. 
 
Several other studies have also demonstrated similar age-related changes in warfarin dose 
requirements.(70-73) Husted et al. concluded that the difference between the mean daily 
warfarin maintenance dose between patients aged 50-60 years and 61-70 years was 
significantly different (p<0.05) in their study of 114 patients on long-term anticoagulant 
therapy.(70) In a longitudinal study of 104 patients on stable warfarin therapy, a 
significant fall in warfarin requirements over time was observed, such that differences in 
warfarin dose requirements were significantly correlated with age differences (r=0.25, 
p<0.01).(71) The superiority of such a longitudinal study is its ability to identify true age-
related changes in dose requirements using the same subjects over time. However, the 
low ‘r value’ indicates that age alone does not explain the fall in dosage requirement. 
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Similarly, the studies by Garcia et al. and Kamali et al. have also shown a significant 
correlation between decreasing dose and increasing age (p<0.001 and r = -0.42, p 
<0.0001 respectively).(72, 73) 
 
The evidence for significant age-related changes in warfarin dose requirements may 
partly be explained by the increased sensitivity in warfarin response observed with 
increasing age. The exact mechanism of the age-related changes in warfarin activity is 
not known. However, two of the studies have attributed it to lower levels of vitamin K 
dependent coagulation factors in older adults.(68, 70) Furthermore, the higher prevalence 
of acute and chronic illnesses such as hypertension, peptic disease, liver disease, 
malignancy, cerebrovascular disease and serious heart disease in older adults may further 
increase the anticoagulant intensity of warfarin and thus increase the risk for serious 
bleeding.(74) For example, an age-related hepatic dysfunction may potentially increase 
the response to warfarin through impaired synthesis of clotting factors and through 
decreased metabolism of warfarin.(75) Thus age may have a potentially confounding 
effect on the risk of bleeding in older adults with several co-morbid conditions. 
 
F. Safety of Warfarin Therapy in Older Adults 
The trend towards increased bleeding in older patients, especially intracranial 
hemorrhage, has been suggested in several studies.(76-79) The safety of treatment with 
warfarin in older patients has been well documented in a systematic review.(80) Out of 
the 8 studies that compared the incidence rate of bleeding in older adults to younger 
individuals in this review, 7 found the incidence rate of bleeding to be almost 2 fold 
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higher in older adults as compared to younger patients, suggesting that there is a need to 
exercise caution with the use of warfarin in older patients. Similarly, increasing age has 
been implicated as a risk factor for increased bleeding experienced by older patients.(74) 
In addition, the authors reported that concomitant use of several medications in older 
adults was also believed to further increase the risk of bleeding. 
 
G. Effect of Age on the Pharmacokinetics of Fluoroquinolones 
Age-related physiologic changes have the potential to affect the pharmacokinetics of 
fluoroquinolones. The most important physiologic change in older adults that affects the 
pharmacokinetics of fluoroquinolones is the decline in renal function. Reduced renal 
function, as a result of reduced glomerular filtration rate, is associated with the aging 
process.(81) Co-morbid medical conditions may exacerbate this decline further. 
Glomerular filtration rate is estimated by the patient’s creatinine clearance and the 
reduction in creatinine clearance in almost 40% when old (>80 years) patients are 
compared to middle-aged patients.(60) This leads to a reduced clearance of drugs such as 
fluoroquinolones that are renally excreted. Levofloxacin is an example of a 
fluoroquinolone that is predominantly renally excreted and compared to other 
fluoroquinolones levofloxacin is the most dependent on renal excretion for elimination. 
High plasma concentrations of levofloxacin are normally achieved for elderly patients at 
recommended doses for younger individuals.(82) Early PK studies of levofloxacin have 
mainly attributed significant differences in PK parameters between younger individuals 
and older adults, to differences in renal functions among the subjects.(82) However, 
results from PK studies done in healthy older adults may not be entirely applicable to 
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older adults with several co-morbid conditions or to frail older adults. In a study of 183 
hospitalized patients with community-acquired pneumonia (CAP), elderly patients 
receiving levofloxacin demonstrated significantly lower clearance (7.2 ± 1.8 vs. 10.4 ± 
3.6, p <0.05), greater elimination half-life (9.8 ± 2.5 vs. 7.4 ± 2.5, p<0.05) and higher 
area under plasma concentration-time curve (AUC)/ minimum inhibitory concentration 
ratios (49.9 ± 9.7 vs. 34.8 ± 9.4, p<0.05) compared to younger patients.(83) 
 
Ciprofloxacin on the other hand, is excreted unchanged renally (60-70% of total serum 
clearance) as well as extra-renally by hepatic routes.(60) In a study that included elderly 
patients and patients with renal impairment, the half-life of ciprofloxacin was almost two 
times the half-life in younger patients (3-4 hours).(84) Ciprofloxacin undergoes 
metabolism via the CYP1A2 and CYP3A4 enzymes. The less potent isomer of warfarin 
(R-warfarin) is also metabolized by CYP1A2 and CYP3A4.(58) It is generally believed, 
that aging decreases hepatic metabolism of medications through CYP1A2 and CYP2C19 
pathways, and hepatic metabolism either decreases or remains normal for medications 
undergoing metabolism via CYP3A4 and CYP2C9. Substantial changes in ciprofloxacin 
metabolism have not been clearly demonstrated in older adults. However, if ciprofloxacin 
and warfarin are inhibiting and competing for the same metabolic pathway, there exist a 
potential for a clinically significant drug interaction. In addition, following a single oral 
250mg dose, the absolute bioavailability of ciprofloxacin was found to be significantly 
higher in older adults compared to younger patients (72% vs. 58%).(60) 
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Finally, age does not have a significant effect on the PK of moxifloxacin since 
moxifloxacin is predominantly metabolized by phase II (conjugation) reactions and 
increasing age does not appear to have an effect on phase II metabolism of drugs.(65) 
Only 15-22% of moxifloxacin is excreted in the urine and no significant decrease in its 
clearance was observed in older subjects with renal function decline.(85) In conclusion, a 
decline in renal function with increasing age leads to reduced clearance of certain 
fluoroquinolones and dosage adjustments may be recommended for such patients. In 
addition, patients above >80 years and those with reduced lean body mass, such as frail 
older patients, should almost always have their quinolone doses adjusted. This is mainly 
due to age-related changes in PK for quinolones that may potentially lead to higher drug 
exposure. 
 
H. Potential Mechanism of Warfarin-Fluoroquinolone Interactions 
Several mechanisms have been proposed for a drug interaction between warfarin and 
antibiotics. Putting these proposed mechanisms into perspective for an older adult would 
help to understand how the risk for a drug interaction might be modified with increasing 
age. CYP1A2 and CYP3A4 enzymes metabolize the less potent isomer of warfarin, i.e. 
R-warfarin.(86) Firstly, fluoroquinolones are inhibitors of CYP1A2 activity and may thus 
inhibit metabolism of warfarin in this manner.(53) Since aging may decrease hepatic 
metabolism of medications through CYP2C9,(65) this may further inhibit metabolism of 
warfarin in older adults. Either or both of these mechanisms may result in increased drug 
exposures for warfarin in older adults. Secondly, antibiotics may impair the production of 
vitamin K by the gastrointestinal flora,(86) Vitamin K is required for coagulopathy and 
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their levels in the body are primarily determined by dietary intake.(86) During an 
infection or in a frail older patient with poor nutritional status, dietary vitamin K levels 
are generally low and may thus lead to increased warfarin sensitivity and over-
anticoagulation. Vulnerable older adults may require closer monitoring with concomitant 
antibiotic use, especially if they are prone to more serious sequelae such as falls resulting 
in serious bleeding events.  
 
Finally, the effect of the infection on warfarin metabolism cannot be underestimated. 
During an infection or inflammation the activity of some CYP450 enzymes may be 
reduced. This may occur due to the secretion of cytokines such as tumor necrosis factor 
(TNF) and interleukins (ILs) which could down-regulate CYP450 enzyme activity, thus 
reducing the metabolism of warfarin.(21) Thus the underlying infection for which the 
antibiotic is prescribed may affect the clearance of warfarin. This is especially true in the 
case of pulmonary infections such as pneumonia, since hepatic metabolism of drugs is 
reduced in the presence of pneumonia.(21) The incidence of community-acquired 
pneumonia has been shown to increase significantly with age, such that almost 80% of all 
cases are in those above 60 years.(55) Similarly, the frequency of urinary tract infections 
is the highest in older adults.(56) Furthermore, due to appetite suppression during an 
infection, vitamin K levels may also be low. Thus increased exposure to warfarin and 
quinolones associated with increasing age, increased sensitivity to warfarin in older 
adults, and effect of age on vitamin K and coagulation may result in an increased risk of 
warfarin-quinolone interactions in older adults.  
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I. Discussion 
There is an age-related increase in sensitivity to warfarin response and the mechanism for 
this has not been entirely established. A possible reason is that older adults may have 
lower levels of vitamin K dependent coagulation factors. Reduced renal function 
associated with increasing age may reduce the clearance of the quinolone antibiotics. 
These factors combined may potentially lead to higher drug exposure for both warfarin 
and quinolones in older adults. Thus an interaction between warfarin and quinolone 
antibiotics in older adults may potentially result in significant elevations of INR and put 
them at greater risk for hemorrhagic complications. Given that hemorrhagic 
complications of warfarin are higher in older adults, understanding the clinical 
significance of the interaction between these two widely used medications may 
potentially help to improve the management of warfarin-antibiotic interactions in older 
adults. Thus there is a need for research in the area of warfarin-quinolones drug-
interactions in older adults, rather than extrapolating what we already know from younger 
populations regarding the clinical significance of this drug interaction. The research 
proposed in this application is significant because it will help us to understand the clinical 
relevance and the risk of co-prescribing warfarin and antibiotics specifically in older 
adult, since they may be the population with a greater risk. 
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CHAPTER 3 
Warfarin Use in Nursing Home Residents: Results from the 
2004 National Nursing Home Survey  
I. Abstract 
Background: Practice guidelines recommend anticoagulation therapy with warfarin for 
stroke prevention in patients with atrial fibrillation (AF). Despite this, warfarin is 
underused in older adults.  
Objective: To determine the prevalence of AF in nursing home (NH) residents and use of 
warfarin or other anti-platelet medications in NH residents with AF, with indications for 
and without contraindications to warfarin use. The secondary objective is to determine 
the factors associated with warfarin use in NH residents with AF. 
Methods: Cross-sectional analysis of prescription and resident data files from the 2004 
National Nursing Home Survey was performed. Residents with a diagnosis of AF were 
identified using ICD-9-CM codes and prescriptions of warfarin and anti-platelet 
medications were identified using Long-term Care Drug Database System (LTCDDS) 
codes. Resident characteristics, stroke risk factors and potential bleeding risk factors 
significant at p<0.10 in chi-square analyses were entered in the final multiple logistic 
regression model to determine the factors associated with warfarin use. All analyses were 
done using SAS 9.2. 
Results: From 13,507 NH residents, 1904 (14%) had a diagnosis for AF and 1767 (13%) 
had a diagnosis for AF, with indications for and without contraindications to warfarin 
use. Of these 1767 residents, 30% were prescribed warfarin and of the remaining 1230 
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resident, 23% received either aspirin or clopidogrel, such that 54% of residents with AF 
did not receive any antithrombotic therapy in the form of warfarin, aspirin, clopidogrel or 
combination of these medications. Factors that were significantly associated with 
increased odds of receiving warfarin were congestive heart failure, previous stroke/ 
transient ischemic attack, deep vein thrombosis/ peripheral embolus, valvular heart 
disease and total number of medications (≥ 6). Factors that were significantly associated 
with reduced odds of receiving warfarin were non-white race, history of gastrointestinal 
bleeding and use of anti-platelets (i.e. clopidogrel).  
Conclusions: AF is common in NH residents and more than half the residents with AF, 
with indications for and no contraindications to warfarin use, were not prescribed either 
warfarin or anti-platelets such as aspirin or clopidogrel, suggesting that anticoagulation 
therapy may be underused in NH residents with AF.  
Keywords: Warfarin, atrial fibrillation, underuse, nursing homes 
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II. Introduction 
The Anticoagulation and Risk Factors in Atrial Fibrillation Study (ATRIA) study, 
estimated that approximately 2.3 million Americans were diagnosed with atrial 
fibrillation (AF) between 1996-1997, and this number is likely to increase 2.5 fold in the 
next 50 years.(1) The age-specific prevalence of AF is the highest in those above 80 years 
(11-12%) as compared to those 55 years and younger (0.1-0.2%).(2) Patients with AF 
have a five-fold increased risk of ischemic stroke; thus prevention of ischemic stroke is 
the primary goal in management of patients with AF. (2) Practice guidelines recommend 
anticoagulation therapy with a vitamin K antagonist, such as warfarin, for the prevention 
of ischemic stroke in these patients.(3-5) For patients who are at increased risk of 
bleeding events or have a contraindication to warfarin, anti-platelet therapy with aspirin 
may be an alternative, although aspirin is not as effective as warfarin in reducing the risk 
of stroke in AF patients.(6, 7) The combination of aspirin and clopidogrel was found to 
be more effective than aspirin alone and may be used in patients for whom warfarin is 
contraindicated.(8) In addition, long-term use of clopidogrel was considered more 
effective than aspirin alone in reducing the risk of thromboembolic events.(9) Ticlopidine 
is no longer used for anti-platelet therapy and according to the Beers criteria its use is 
discouraged in older adults.(10) Therefore, adjusted-dose warfarin still remains the most 
effective therapy for stroke prevention. 
 
Currently, more than 1.6 million older Americans are residing in nursing homes. The 
prevalence of AF is also higher in NH residents (7.5-17%) as compared to community-
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dwelling older adults.(14, 16) This may be a reflection of the higher age and increased 
prevalence of cardiovascular diseases among NH residents. In addition, NH residents are 
generally frailer as compared to community-dwelling older adults. Frail patients are less 
likely to receive warfarin, and this may partly be due to fear of hemorrhagic 
complications.(17) The relationship between increasing age and hemorrhagic 
complications is such that the tendency towards increased bleeding with oral 
anticoagulants is higher in older adults as compared to younger patients.(18) In addition 
to the increased incidence of bleeding, the severity of bleeding events has been shown to 
be greater in older adults.(19) Several studies have shown that the response to warfarin 
therapy increases with age, both in the early induction phase and during the long-term 
maintenance phase.(20) Age-related changes in warfarin dose requirements have been 
demonstrated in cross-sectional studies, (21-25) as well as in longitudinal studies.(22, 26) 
The risk of falls is higher in NH residents, such that the mean fall rate of 1.5 falls/ bed per 
year is three times the rate for community-dwelling older adults.(27) Higher prevalence 
of co-morbid conditions such as, congestive heart failure, hypertension, malignancy, 
ischemic stroke, peptic ulcer disease, liver disease, in older adults may also lead to an 
increased risk of bleeding.(19, 20) Thus, changes in homeostasis of coagulation 
associated with increasing age, increased fall risk and high prevalence of multiple co-
morbid conditions may put NH residents at an increased risk of bleeding events. Due to 
perceived increased risk of bleeding, nursing home residents may be less likely to receive 
a prescription for warfarin, in spite of the presence of more than one stroke risk factor. 
Gurwitz et al have shown adverse warfarin-related events to be common among NH 
residents, of which 29% were judged to be preventable.(28) However, the benefits of 
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warfarin therapy in reducing the incidence of thromboembolic stroke have been 
demonstrated for patients with AF who do not have contraindications to warfarin, 
including patients that are 70 years and older.(29-31)  
 
Despite the benefits of anticoagulation therapy with warfarin in AF patients, studies have 
reported an under-use of this drug in older adults.(11-13) Few studies have specifically 
documented the prevalence of AF and under-use of warfarin in NH residents and none of 
these used a nationally representative sample of NH residents.(14-16, 32) Some of these 
studies were done more than 10 years ago, and since then new anti-platelet agents such as 
clopidogrel have become available for secondary stroke prevention. Thus there is limited 
national level data on the prevalence of AF and use of warfarin in NH residents. The NH 
population is of interest due to their higher mean age and thus higher prevalence of AF. 
In addition, the increased prevalence of cardiovascular diseases in this population is a 
concern since some of these conditions may be potential stroke risk factors. Determining 
patterns of warfarin and anti-platelet medication use in NH residents would increase our 
understanding of treatment choices made for stroke prevention in this older population. 
Identifying resident characteristics or risk factors for stroke and bleeding that are related 
to warfarin use may further help to address the issue of underuse of anticoagulation 
therapy, if any. Therefore, the primary aim of this study was to determine the prevalence 
of AF in nursing home residents and use of warfarin or other anti-platelet medications in 
NH residents with AF, with indications for and without contraindications warfarin use. 
The secondary aim is to determine the factors associated with warfarin use in NH 
residents with AF.  
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III. Methods 
A. Data source and study sample: This is a cross-sectional analysis of the prescription 
and the resident data file from the 2004 National Nursing Home Survey (NNHS). This 
survey uses two-stage sampling to obtain a representative sample of nursing home 
residents in the United States and is conducted periodically by the Centers for Disease 
Control and Prevention. The 2004 data is the more recent wave of the NNHS and 
contains information on 13,504 nursing home residents. The NNHS dataset is available 
for public use and was accessed after receiving approval from the Virginia 
Commonwealth University Institutional Review Board. More details of the NNHS may 
be found at http://www.cdc.gov/nchs/nnhs.htm.  
 
The study sample included a nationally representative sample of NH residents with AF. 
Residents with a diagnosis for AF were identified using the International Classification 
of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code 427.31. AF coding 
has been shown to have high sensitivity (81-91%) and specificity (83-100%) in a 
previous study that determined the accuracy of coding of stroke risk factors such as AF, 
by using ECG and physician history notes as the gold standard.(33) This study was not 
specific to the NNHS, but previous studies have also used the ICD-9-CM diagnostic code 
427.31 to identify eligible patients with AF from large claims databases,(13, 34) or from 
hospital notes and discharge records.(12, 35) 
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From the full AF sample, residents for whom warfarin was not indicated according to the 
2001 American College of Cardiology/ American Heart Association (ACC/AHA) 
guidelines for management of patients with AF were excluded.(36) The 2001 guidelines 
were applicable at the time of the 2004 NNHS sample. According to the ACC/ AHA 
guidelines, warfarin was not recommended for men and women < 60 years of age with or 
without stroke/ thromboembolism risk factors and men 60-74 years of age without 
thromboembolism/ stroke risk factors. This sample was further reduced to those residents 
for whom warfarin is indicated, i.e. women 60-74 years of age with or without stroke/ 
thromboembolism risk factors, men 60-74 with stroke/ thromboembolism risk factors and 
both men and women 75+ with and without stroke/ thromboembolism risk factors. 
Stroke/ thromboembolism risk factors included congestive heart failure, hypertension, 
diabetes mellitus, previous stroke or transient ischemic attack (TIA), coronary heart 
disease, deep vein thrombosis or peripheral embolus and valvular heart disease. The 
stroke risk for each resident with AF was also calculated using the CHADS2 (congestive 
heart failure, hypertension, age ≥ 75 years, diabetes mellitus and prior stroke or transient 
ischemic attack) index. This score is usually calculated to quantify the stroke risk for 
patients with AF and may help to guide suitable antithrombotic therapy.(37)  
 
In addition, residents for whom warfarin is contraindicated according to the Coumadin® 
package insert were excluded.(38) These contraindications included hemorrhagic 
tendencies or blood dyscrasias such as thrombocytopenia, active GI ulceration and recent 
surgery. Furthermore, variables for potential bleeding risk factors were created. These 
included age ≥ 65, renal failure/ chronic kidney disease, falls history, dementia, hepatic 
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disease, history of gastrointestinal bleeding, myocardial infarction, malignancy, use of 
warfarin interacting medications such as anti-platelets (i.e. clopidogrel) and NSAIDs. 
These potential bleeding risk factors were identified from the Coumadin® package insert, 
the Outpatient Bleeding Risk Index and the HAS-BLED score.(38-40) Variables for 
thromboembolism risk factors, contraindications for warfarin use and potential bleeding 
risk factors were created using information from primary and secondary diagnoses for 
NH admission and recent ER visits/ hospitalization from NNHS resident questionnaire 
and LTC medication data. The ICD-9-CM diagnosis codes used to identify residents with 
the above variables have been provided in Appendix A. These codes have been validated 
in previous studies and were identified using the ICD-9 coding manual and previous 
literature.(33, 41-48) These ICD-9 codes have been used previously in other studies.(49, 
50) In addition to ICD-9 codes, NAMCS reason for visit codes were used to identify 
residents with contraindications to warfarin use. (Appendix B) A resident was said to 
have a positive fall history if they had a documented fall in the past 31-180 days, as per 
the definition used by the 2004 NNHS. Use of anti-platelets and NSAIDs were 
determined using the LTCDDS codes listed in Appendix C. 
 
B. Drug exposure: The NNHS collected medication data using the medication 
administration records (MARs) in the resident’s medical record. For each sampled 
resident the designated NH respondent answered medication questions such as ‘what 
medications were taken by the resident during the 24 hours the day before the facility 
interview?’ and ‘what medications were taken regularly by the resident but not during the 
24 hours before the facility interview?’ The interviewer was allowed to enter up to 25 
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medications for each question using the computer-assisted personal interviewing (CAPI) 
instrument. The primary outcome of this analysis is the use of warfarin in NH residents 
with AF, with indications for and without contraindications to warfarin use. The Long-
term Care Drug Database System (LTCDDS) codes were used to determine whether 
residents with AF received a prescription for warfarin or other anti-platelet agents, such 
as aspirin (at daily dose from 81mg to 325 mg to distinguish from its use as an analgesic 
and anti-inflammatory), clopidogrel, ticlopidine and dipyridamole.  The LTCDDS codes 
for the above medications are provided in Appendix C and were used to scan all 25 
medications for each sampled resident. Prevalence of warfarin use and use of other anti-
platelet drugs in these residents with AF was determined.  
 
C. Statistical analysis: The prescription and resident data files were merged for the 
purpose of the analysis based on the resident ID (RESNUM). Sampling weights were 
provided in the NNHS, and these were used to determine national estimates of 
medication use and prevalence. Descriptive statistics were used to summarize the 
characteristics of residents with AF. Since the data were normally distributed, mean and 
SD were used to describe continuous outcomes. Thus the dependent variable in this 
analysis was prescription of warfarin. Chi-square analysis was used to determine the 
association between warfarin use and resident characteristics such as age (60-79, 80-90, 
≥90), sex, race (white and non-white), ethnicity (Hispanic and non-Hispanic), length of 
stay (≥ 90 days, < 90 days), total number of medications (0-5, 6-15, 16-30), stroke risk 
factors (congestive heart failure (CHF), hypertension, diabetes mellitus, previous stroke 
or TIA, DVT or peripheral embolus, valvular heart disease, CHADS2 score (0-1, 2, 3, 4-
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5) and potential bleeding risk factors (renal failure/ CKD, dementia, history of falls, 
bleeding history, myocardial infarction, malignancy, use of anti-platelets or NSAIDs). 
Total number of medications was classified as either 0-5, 6-15 or 16-30, since surveys on 
patients living in nursing homes showed that these residents took on average 6-8 different 
drugs simultaneously. (51) Thus we would expect a majority of NH residents to be within 
the 6-15 category of total number of medication. The significance level for variables in 
the bivariate chi-square analysis was set to alpha = 0.10. Factors that were found to be 
significantly associated with warfarin use in the bivariate chi-square analysis were 
included in the final multiple logistic regression model. Model building was done using 
the stepwise selection option under PROC LOGISTIC with SLENTRY (significance 
level for entering) set at 0.10 and SLSTAY (significance level for stay) set at 0.15.  All 
analyses were conducted using SAS software, version 9.2 (SAS Institute Inc, Cary, NC, 
USA). P-values < 0.05 were considered significant. Survey procedures such as 
SURVEYMEANS, SURVEYFREQ and SURVEYLOGISTIC were used, since these 
procedures take into account the sampling weights.  
 
IV. Results 
A. Demographics and Anticoagulant Use 
From the 13,507 NH residents sampled in the 2004 NNHS, a total of 1904 (14%) 
residents had a diagnosis for AF. Of these 1904 residents with AF, 64 (3.4%) residents 
did not have any risk factors for stroke and were excluded from the analytic sample. 
Further from the remaining 1840 residents with an indication for warfarin use, 1767 
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residents had no contraindications to warfarin use. Thus from the total 13,507 NH 
residents, 1767 (13%) had a diagnosis for AF with indications for and no 
contraindications to warfarin use. The mean age (SD) of 1767 residents with AF was 85.6 
(7.4) years and the range was 61-100 years. From this, 1259 (71%) residents were 
females. The mean (SD) number of medications prescribed for residents with AF was 10 
(4) and the range was 0-24 medications. 
 
Warfarin was prescribed in 537 (30%) residents with AF and of the remaining 1230 
(70%) who did not receive warfarin, 278 (23%) received anti-platelet therapy either in the 
form of aspirin or clopidogrel. Figure 1 outlines the use of warfarin and anti-platelet 
medications in the 1767 residents with AF. As shown in Figure 2, 954 (54%) residents 
with AF did not receive any form of antithrombotic therapy in the form of warfarin, 
aspirin, clopidogrel or combination of these medications. Ticlopidine and dipyridamole 
were not prescribed in any resident. Table 1 summarizes the demographics, risk factors 
for stroke, residents CHADS2 score and potential risk factors for bleeding, stratified by 
warfarin-users and non-users. Since the percentage of residents with hepatic failure was 
<1% this variable was not included in the analysis. The percentages included in this table 
are based on weighted frequencies calculated using the sampling weights provided and 
are thus national estimates.  
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Table 1: Characteristics of nursing home residents with atrial fibrillation, with 
indications for and no contraindications to warfarin, stratified by warfarin use 
 
Resident Characteristic Warfarin users 
N=58,779 (31%) 
% 
Warfarin non-users 
N=133,284 (69%) 
% 
p-valuea 
Age groups (years) 
  60-79 
  80-89 
  ≥ 90 
Sex 
  Male 
  Female 
 
22 
53 
25 
 
28 
72 
 
96 
4 
 
3 
97 
 
24 
76 
 
7 
81 
12 
 
40 
63 
24 
34 
31 
8 
4 
 
 
40 
27 
26 
 
20 
45 
35 
 
30 
70 
 
90 
10 
 
2 
98 
 
22 
78 
 
16 
78 
6 
 
35 
61 
23 
24 
30 
3 
2 
 
 
50 
26 
19 
 
0.0007* 
 
 
 
0.5024 
Race 
  White 
  Non-white 
 
0.0021* 
Ethnicity 
  Hispanic 
  Non-hispanic 
 
0.1785 
Length of stay (days) 
  < 90 
  ≥ 90 
 
0.3415 
Total no. medications 
  0-5 
  6-15 
  16-30 
 
<0.0001* 
Stroke Risk Factors† 
  Congestive heart failure 
  Hypertension 
  Diabetes mellitus 
  Previous stroke/ TIA 
  Coronary heart disease 
  DVTc/ peripheral 
  embolus 
  Valvular heart disease 
 
0.0948* 
0.5477 
0.7505 
0.0002* 
0.7289 
<0.0001* 
0.0281* 
CHADS2 score for stroke 
risk† 
  0-1 
  2 
 
 
0.0026* 
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  3 
  4-5 
7 
 
4 
6 
29 
2 
27 
4 
 
 
4 
13 
5 
 
7 
5 
28 
3 
26 
6 
 
 
24 
10 
Bleeding risk factors† 
  History of GI bleeding 
  Dementia 
  Falls (past 31-180 days) 
  Myocardial infarction 
  CKD/ renal failure 
  Malignancy 
  Use of warfarin-      
  interacting       
  drugs: 
(i) Anti-platelets 
(ii) NSAIDs 
 
0.0150* 
0.2750 
0.9570 
0.3043 
0.7479 
0.2056 
 
 
<0.0001* 
0.0414* 
† not mutually exclusive 
a p-value from chi-square analysis between warfarin users and non-users and resident 
characteristics  
*p-value significant at <0.10 
 
TIA = transient ischemic attack; CKD = chronic kidney disease; NSAIDs = Non-
steroidal anti-inflammatory drugs; CHADS2 = congestive heart failure, hypertension, age 
≥ 75 years, diabetes mellitus and prior stroke or transient ischemic attack  
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Figure 1: Summary of use of warfarin and other anti-platelet medications in eligible 
nursing home residents with atrial fibrillation 
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Figure 2: Use of warfarin and other anti-platelet medications by nursing home 
residents with atrial fibrillation (n = 1767) 
 
 
Combination therapy includes (i) warfarin and aspirin (n=17) (ii) aspirin and clopidogrel 
(n=20) (iii) warfarin and clopidogrel (n=4) 
 
B. Factors associated with warfarin use 
Table 2 presents the results of the multivariable analysis with the adjusted odds ratio 
(OR), 95% CI and p-value for factors that were found to be significantly associated with 
warfarin use. These factors include age, race, total number of medications, stroke risk 
factors (CHF, previous stroke/ TIA, DVT/ peripheral embolism, and valvular heart 
disease) and potential bleeding risk factors (history of GI bleeding and use of anti-
platelets or NSAIDs). 
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The association of age with warfarin use was such that residents in the ≥ 90 years age 
group were less likely to be receiving warfarin as compared to the 60-79 years age group. 
(OR=0.61, 95%CI = 0.44-0.85). Non-white residents had significantly lower odds for 
receiving warfarin as compared to white residents (OR= 0.37; 95% CI = 0.22-0.63)). 
With an increasing number of prescribed medications, residents were more likely to be 
receiving warfarin, such that residents taking 6-15 and 16-30 medications were more 
likely to be receiving warfarin as compared to those taking 0-5 medications (OR= 3.03, 
95% CI = 2.03-4.50 and OR= 7.41 , 95% CI = 4.27-12.87 respectively). Among the 
stroke risk factors, residents with CHF (OR=1.29, 95% CI=1.03-1.62), previous stroke 
event/ TIA (OR=2.26, 95% CI=1.77-2.90), DVT (OR=5.83, 95% CI=3.18-10.70) and 
valvular heart disease (OR=1.77, 95% CI=0.93-3.39) were more likely to be receiving 
warfarin. The only potential bleeding risk factors for warfarin that was significantly 
associated with warfarin use was history of GI bleeding and use of anti-platelets (i.e. 
clopidogrel), such that residents with a prior GI bleeding event (OR = 0.51, 95% 
CI=0.31-0.84) and those using anti-platelets (OR=0.10, 95% CI=0.06-0.17) were less 
likely to be prescribed warfarin. 
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Table 2: Factors associated with warfarin use in nursing home residents with atrial 
fibrillation, with indications for and no contraindications to warfarin 
 
Variable Adjusted Odds Ratio (95% CI) p-value 
Age 
  60-79 
  80-89 
  ≥ 90 
 
1.00  
1.05 (0.79 – 1.41) 
0.61 (0.44 – 0.85) 
 
0.0001 
Race 
  White 
  Non-White 
 
1.00 
0.37 (0.22– 0.63) 
 
0.0003 
Total no. medications 
  0-5 
  6-15 
  16-30 
Stroke risk factors 
 
1.00 
3.03 (2.04 – 4.52) 
7.44 (4.28 – 12.93) 
 
<0.0001 
Congestive heart failure 1.29 (1.03 – 1.63) 0.0275 
Previous stroke/ TIA 2.26 (1.76 – 2.89) <0.0001 
DVT/ peripheral embolus 5.83 (3.17 – 10.70) <0.0001 
Valvular heart disease 
Bleeding risk factors 
1.76 (0.92 – 3.37) 0.082 
History of GI bleeding 0.48 (0.30 – 0.78) 0.0031 
Use of anti-platelets 0.10 (0.06 – 0.17) <0.0001 
 
V. Discussion 
A. Underuse of warfarin in NH residents: 
The results of this cross-sectional analysis showed that 14% of all NH residents had a 
diagnosis of AF and 13% of all NH residents had a diagnosis of AF with indications for 
and without contraindications to warfarin use, of which about 30% received 
anticoagulation therapy with warfarin. Furthermore, about 23% of residents who did not 
receive warfarin, received secondary stroke prophylaxis with either aspirin or 
clopidogrel. Thus 54% of NH residents did not receive either warfarin or antiplatelet 
therapy with aspirin or clopidogrel. It was not surprising that none of the residents 
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received ticlopidine, since the use of this agent is discouraged in older adults.(10) 
Previous studies have found the prevalence of AF in NH residents to be around 7.5-17%; 
however, these studies were done more than 10 years ago.(14-16) The 30% rate of 
warfarin use in NH residents reported in this study was similar to what has been reported 
previously for NH residents. Gurwitz et al. reported that 32% of patients with AF were 
being treated with warfarin across 30 long-term care (LTC) facilities,(15) McCormick et 
al. reported 42% warfarin use in NH patients with AF(16) and Lackner et al. reported that 
only 20% of NH patients with nonvalvular AF were being treated with warfarin as per the 
ACCP guidelines.(14) Similar to these studies the results of this cross-sectional analysis 
suggest that anticoagulation therapy with warfarin or anti-platelet therapy with aspirin or 
clopidogrel may be underused in this nationally representative sample of NH residents. 
 
Major practice guidelines, such as those by the American College of Chest Physicians 
(ACCP), the American Heart Association/ American Stroke Association and American 
College of Cardiology/ American Heart Association recommend warfarin as a class I 
recommendation for stroke prevention in patients with AF. (3-5) Furthermore, the ACCP 
guidelines have been adapted for use in older adults by the American Geriatrics Society 
and their recommendations also include the use of warfarin for prevention of stroke in 
patients with nonvalvular AF and without a contraindication to warfarin.(52) Thus in 
spite of these practice guidelines, underuse of warfarin is consistently being reported for 
older adults, not only in NH residents but also in community dwelling and hospitalized 
older adults.(34, 53-55) Safety of warfarin therapy in NH residents may be a cause of 
concern, leading to its underuse. A study done in 25 NHs by Gurwitz et al. found that 
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87% of all the 720 warfarin-related adverse events were minor, 11% were deemed serious 
and 2% were considered life-threatening or fatal.(28) Furthermore, 29% of adverse 
warfarin-related events were deemed preventable in NH settings.(28) 
There may be several barriers to prescribing warfarin and these may be classified as 
patient, physician and health care system-related barriers.(56) Important patient-related 
barriers included increasing age, perceived embolic risk and perceived risk for 
hemorrhage and the most important and consistent physician-related barrier was the 
physician’s perception of the benefit vs. risk of therapy.(56) A survey that assessed the 
attitude of LTC physicians towards warfarin use showed that 34% of the physicians 
believed the benefits of warfarin only slightly outweighed the risks, and 19% believed 
that the risks outweigh the benefits.(57) Future research may help to determine whether 
these barriers relate to possible warfarin underuse in NH residents.  
 
The patterns of anti-coagulation use in NH settings for patients with AF may change with 
the newly approved oral anticoagulant, dabigatran. Since this medication was recently 
approved, little is known about the patterns of use and safety profile associated with 
dabigatran in the NH setting. Some features that may seem attractive for use of 
dabigatran are fixed doses, renal excretion and no monitoring of INR required.(58) In 
addition, dabigatran may be more expensive but would have lower costs associated with 
monitoring the patient.(59) However, lack of monitoring of older adults on 
anticoagulation therapy, especially frail nursing home residents, may be a cause of 
concern given the risks associated with anticoagulation therapy in general. Two cases of 
dabigatran-related adverse events were recently reported in 2 older frail women, from 
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which one had a fatal outcome.(60) Both women had low body weight and reduced renal 
function. Thus LTC physicians may need to be cautious while prescribing dabigatran to 
frail patients with moderate or severe renal insufficiency until there is more data available 
regarding its use in older adults. It would be interesting to know from future studies 
whether LTC physicians have started prescribing dabigatran to NH residents with AF, 
and how these prescribing patterns affect the possible underuse of anticoagulation in NH 
settings. Given the long track record of warfarin usage and knowledge about its potential 
adverse effects, it may be possible that LTC physicians would want to continue warfarin 
therapy for patients that are already stable on it.  
 
B. Factors associated with warfarin use: 
Residents aged 90 years and above were less likely to receive a prescription for warfarin 
as compared to those in the 60-79 year age group. Previous studies have also reported 
older age, usually ≥85 years, to be a predictor of warfarin underuse.(61-63) There is 
evidence to support an increased bleeding risk in patients >80 years.(64) Fear of 
increased bleeding risk, frailty and increased risk for falling may have led to a decreased 
use of warfarin in the oldest resident age group. This may raise a particular concern for 
warfarin therapy in those aged ≥ 90 years and above since older patients appear to be at 
the highest risk of ischemic stroke if not treated and have the highest absolute reduction 
in risk of ischemic stroke when treated.(65) Thus the oldest patients who are more likely 
to need and benefit from warfarin therapy are also at higher risk of warfarin-related 
bleeding events. Residents of the non-white race were less likely to receive warfarin as 
compared to whites. This kind of a racial difference in warfarin use has been shown in 
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previous studies as well.(11, 49) Residents using 6-15 or 16-30 total number of 
medications were more likely to be prescribed warfarin than those receiving 0-5 
medications. This association may have important implications since warfarin is known 
to undergo interactions with several medications.(66) A study that assessed the use of 
warfarin-interacting medications in long-term care found that 79% of NH residents were 
prescribed at least one warfarin-interacting medication and these residents were found to 
spend significantly less time in the therapeutic range.(67) Future studies could provide 
more information on what percentage of these medications may be potentially interacting 
with warfarin. As expected, residents with stroke risk factors such as CHF, previous 
stroke/ TIA, DVT/ PE and VHD were more likely to receive warfarin as a measure for 
stroke prophylaxis. While history of stroke or TIA has consistently been reported as a 
predictor of warfarin use, the results for the other stroke risk factors have varied across 
studies.(35, 62, 63) The finding that CHADS2 score was not part of the final logistic 
model in spite of it being an important predictor of stroke risk may seem unusual. A 
possible reason for this may be that most of the variables comprising this index were 
already inputted as independent predictors in to the logistic model. Two of these 
CHADS2 variables, CHF and prior stroke/ TIA were found to be significant predictors of 
warfarin use. Thus due to reasons of collinearity of the CHADS2 score with other 
variables, it may not have been significant in the final model. Of all the potential bleeding 
risk factors that were included in this study, only history of GI bleeding and use of anti-
platelets was associated with a decrease in warfarin use. History of GI bleeding has been 
found to be a significant predictor in previous studies.(35, 61, 62) It seems logical that 
residents receiving warfarin were less likely to be prescribed anti-platelets (i.e. 
	   	   	  	  	  	  	  
	   82	  
clopidogrel) since these residents with AF are already receiving anticoagulation therapy. 
A secondary reason may be the fear of warfarin-clopidogrel drug interaction. On the 
other hand, there were no significant differences in NSAIDs prescriptions among 
warfarin users and non-users.  
 
Based on the results of this study, the use of warfarin could be potentially increased in 
some ways. If fear of bleeding events is a concern for those above the age of 90 years, 
use of some of the bleeding risk scores such as HEMOR2RHAGES, HAS-BLED or the 
Outpatient bleeding risk Index, in conjunction with the stroke risk index, such as 
CHADS2 may help to assess the risk versus benefits of warfarin therapy.(37, 40, 68, 69) 
Interventions to increase the use of warfarin in the minority NH population could be 
implemented. Suboptimal effectiveness and less frequent monitoring of warfarin among 
black and Hispanic Medicare beneficiaries as compared to whites have been shown in a 
previous study.(11) In addition, genetic polymorphisms may affect the sensitivity of 
warfarin and are known to vary in prevalence according to race.(11) Thus possible 
reasons for underuse of anticoagulation therapy in non-whites could be an area of future 
research. If suboptimal effectiveness, lower monitoring and genetic polymorphisms are 
found to be potential reasons for decreased warfarin use in non-whites, alternate 
strategies for anticoagulation, such as dabigatran, could be employed for these patients.   
Some limitations of this study may be identified. Due to the nature of the data we could 
not confirm the diagnosis of AF clinically by means of an electrocardiogram and whether 
residents had paroxysmal, persistent or permanent AF.  It was also not possible to know 
if patient was actively in AF or had been successfully cardioverted.  Since patients go in 
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and out of AF, it is difficult to know if they are currently in AF at the time of assessment 
from the survey. Data on the type of medication order (i.e. standing, routine, or PRN), 
dosage, strength, route, or frequency information was not collected. The accuracy of 
stroke/ TIA codes (434-436) reported by some studies was poor.(42, 45) Determining 
‘suitable’ ICD-9-CM codes to identify subjects of interest in epidemiological studies such 
as this will always be a shortcoming. One way of accounting for this limitation is to 
restrict the analysis to ICD-9 codes that have been used frequently in prior studies,(41, 
49, 50) and codes with acceptable levels of sensitivity, specificity and positive predictive 
values (PPVs). Stroke and stroke risk factors such as atrial fibrillation, coronary artery 
disease, diabetes mellitus and hypertension have been coded with sensitivity from 81% to 
91% and specificity ranging from 83% to 100%.(33)The potential bleeding risk factors 
and stroke risk factors included only those variables for which data were collected in the 
NNHS. Information on additional bleeding risk factors, such as vascular malformation, 
uncontrolled hypertension, seizure disorders, fluctuating INR values and pharmacokinetic 
drug interactions, or stroke risk factors such as left atrial size > 45mm and left ventricular 
ejection fraction <40% or contraindications to warfarin use such as planned surgery 
within a month, chronic alcohol abuse, poor compliance, patient refusal of warfarin and 
warfarin allergy was not available. In addition, there was a lack of knowledge regarding 
previous warfarin use. A resident may have been on warfarin in the past but may have 
been discontinued from it for reasons that were not captured in the survey. However, the 
analysis included all available stroke and bleeding risk factors to determine residents with 
AF who should potentially be receiving warfarin. Additionally, the validity of coding of 
warfarin and antiplatelets medications in the LTCDDS is not routinely checked. The 
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information on medications used by the resident is collected based on review of the 
medication administration record. Since this is supposed to be the record of actual 
medication administration, we would expect it to be valid; however, there may be some 
error and this is a known limitation of this type of data. According to the NNHS, history 
of falls was defined as those who ‘fell in past 31-180 days’. Thus this definition does not 
include residents who had a fall prior to 180 days or within 31 days from the time of the 
survey, suggesting that the percentage of those with falls may have been higher than what 
was actually reported in this analysis. Since this was a cross-sectional analysis it was not 
possible to determine whether residents who did not receive anticoagulation were more 
likely to have adverse stroke or thromboemobolic outcomes as compared to those who 
received stroke prophylaxis. Finally, due to the cross-sectional nature of the study it is not 
possible to make any causal inferences for the factors associated with warfarin use. Thus 
the term ‘predictors’ was avoided for any of the factors that were found to be 
significantly associated with warfarin use. The study provided the prevalence of AF and 
warfarin use in NH residents at one point in time; the results may differ if another time 
frame had been chosen given the new oral anticoagulant, dabigatran that was recently 
approved in 2010. However, the 2004 NNHS survey was the mostly recent wave of the 
survey and no other study has recently determined these national prevalence estimates of 
AF for NH residents. These rates were not comparable to previous estimates of the 
NNHS since this was the first time in the survey’s history that medication data was 
collected.  
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VI. Conclusion 
The overall prevalence of AF in NH residents was 14%, such that 13% of the total 
number of residents had a diagnosis for AF with indications for and no contraindications 
to warfarin use.  The total rate of warfarin use in these residents with AF was about 30%, 
confirming the results of previous studies that suggest an underuse of warfarin in NH 
residents with AF. Age ≥ 90 years, non-white race, total number of medications, CHF, 
previous stroke/ TIA, DVT/ PE, VHD, GI bleeding history and use of anti-platelets were 
factors that were significant predictors of warfarin use. Suggestions for future research 
include development of effective strategies to impact anticoagulation prescribing patterns 
in order to ensure that NH residents most likely to benefit from anticoagulation therapy 
are actually receiving it. Furthermore, it would be interesting to know whether a change 
in anticoagulation prescribing patterns in NH residents would lead to improved patient 
outcomes in terms of reduced stroke rates and reduced adverse bleeding outcomes. 
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CHAPTER 4 
Warfarin-Antibiotic Interactions in Older Adults of an 
Outpatient Anticoagulation Clinic 
        I. Abstract 
Background: Several drugs may interact with warfarin to cause an increase in its 
anticoagulant activity. There are conflicting reports on the nature of warfarin-antibiotic 
interactions and data on outcomes of over-anticoagulation associated with warfarin-
antibiotic interactions is limited in older patients 
Objective: To determine the effect of oral antibiotics, such as amoxicillin, azithromycin, 
cephalexin, ciprofloxacin, levofloxacin and moxifloxacin, on the international normalized 
ratio (INR) in patients on stable warfarin therapy, aged 65 years or above, and to 
determine and compare the effect of warfarin-antibiotic interactions on secondary 
outcomes of over-anticoagulation. 
Methods: This is a retrospective cohort study utilizing data from a medical record review 
of patients from an outpatient anticoagulation clinic at a Veterans Affairs medical center. 
Patients aged 65 years or above, who were on stable warfarin therapy and received a 
prescription of the antibiotics of interest, during the period from January 1st, 2003 to 
March 1st, 2011, were included. Depending on the availability of INR values in the 
anticoagulation clinic notes, two INR values were recorded before antibiotic start date, 
i.e. pre-antibiotic INR 1 and 2, and two INR values were recorded after start of antibiotic, 
i.e. post-antibiotic INR 1 and 2. Mixed-effects repeated measures ANOVA model was 
used to determine the effect of antibiotics on the mean change in patient’s INR over these 
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four periods of time. The secondary outcomes of interest were percentage of patients 
whose warfarin dose was adjusted/ withheld, INR > therapeutic, INR increase >1, INR 
increase >2, absolute INR ≥ 4 or ≥ 5, vitamin K administration or major/ minor bleeding 
events. The Fisher’s exact test was used to test whether there was an association between 
the type of antibiotic and the above secondary outcomes of over-anticoagulation, using 
cephalexin as the control. Statistical significance was defined as a p-value of < 0.05. All 
analyses were done using SAS 9.2 (SAS Institute Inc, Cary, NC, USA). 
Results: There were 364 prescriptions of warfarin-antibiotics in a total of 205 patients 
during the study period. The ANOVA model indicated that there was a significant 
interaction between antibiotic and time (F (15, 358) = 1.9); p-value=0.0221). There was a 
significant increase in INR values from time point 2 to 3 for amoxicillin (p=0.0019), 
azithromycin (p<0.0001), ciprofloxacin (p=0.002), levofloxacin (p<0.0001) and 
moxifloxacin (p<0.0001). There was no significant increase in INR for cephalexin 
between time point 2 and 3 (p=0.2807). The Fisher’s exact test indicated that there was a 
significant association between the type of antibiotic and secondary outcomes. Overall, 
the percentage of patients with warfarin dose withheld, INR > therapeutic, INR increase 
> 1, were significantly greater in the azithromycin, ciprofloxacin, levofloxacin and 
moxifloxacin group as compared to cephalexin (p<0.05 for all antibiotics). No bleeding 
events were reported in any of the patients. 
Conclusion: Amoxicillin, azithromycin and fluoroquinolone antibiotics such as 
ciprofloxacin, levofloxacin and moxifloxacin, lead to a significant increase in INR values 
post-antibiotic use in older patients, when taken concomitantly with warfarin. However, 
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this increase in post-antibiotic INR did not lead to clinically significant outcomes of 
bleeding or hospitalization. Thus antibiotics may be prescribed to older adults on 
warfarin therapy; however, increased INR monitoring may be required to ensure the INR 
remains within therapeutic range during the course of antibiotic therapy. 
Keywords: Warfarin, antibiotics, drug interactions, older adults 
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II. Introduction 
Warfarin is the most widely used oral anticoagulant and its use is the highest in older 
adults due to the increased prevalence of conditions such as atrial fibrillation and other 
thromboembolic disorders with advancing age.(1) Warfarin therapy may be complicated 
by several factors and maintaining therapeutic levels of warfarin is challenging since it is 
a drug with a narrow therapeutic index and it exhibits considerable variability in dose 
response.(2) Several medications may undergo a pharmacokinetic or pharmacodynamic 
interaction with warfarin, thus increasing the risk of adverse outcome of over-
anticoagulation. Drug interactions with warfarin were ranked at number 3 in a list of the 
top 30 adverse events reported for warfarin in the FDA’s Adverse Events Reporting 
system, for the period from June 2003 to July 2006.(3) The most recent systematic review 
on warfarin-drug interactions recommends exercising caution while prescribing 
antibiotics to patients on warfarin, since antibiotics may cause a change in the patient’s 
hematological response to warfarin.(4) The antibiotic classes that were listed include 
fluoroquinolones, macrolides, tetracyclines and penicillins. From the list of top 10 
dangerous drug interactions in nursing home residents, developed by the American 
Society of Consultant Pharmacists as one of the initiatives of their Multidisciplinary 
Medication Management Program, 5 of these interactions involved warfarin and 3 of 
these were due to warfarin-antibiotic combinations such as sulfa drugs, macrolides and 
quinolones.(5)  
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The risk of an interaction may be higher in older adults due to age-related physiologic 
changes that may result in altered pharmacodynamic response for warfarin,(6) and altered 
pharmacokinetics of antibiotics, such as fluoroquinolones.(7) However, the literature fails 
to support the increased risk of bleeding events or over-anticoagulation with warfarin-
antibiotic combinations.(8) Some of these studies were done in settings with close 
anticoagulation monitoring. However, if there was no dose reduction or holding of doses 
the risk of complications may be higher. The most recent review that evaluated the 
possibility of increased anticoagulation due to warfarin-quinolone interactions concluded 
that “there are no consistent data to support the claim of an increased anticoagulation 
response in patients receiving warfarin and any of the three commonly prescribed 
fluoroquinolones”.(9) The clinical evidence for warfarin-antibiotic interactions in older 
adults is very limited and most of the evidence comes from case reports and case 
series,(10-13) or from studies with very few subjects.(14-17) 
 
Due to the conflicting nature of the reports on warfarin-antibiotic interactions and lack of 
studies done specifically in older patients, there is a need to understand the clinical 
relevance of warfarin-antibiotic interactions in older adults. The primary objective of the 
study was to determine the effect of antibiotics on INR values over time in patients on 
stable warfarin therapy from an outpatient warfarin clinic. The secondary objective was 
to determine and compare the effect on secondary outcomes of over-anticoagulation 
caused by the combination of warfarin-antibiotics since this may further help us to 
understand the potential clinical impact of supratherapeutic INR values due to warfarin-
antibiotic interactions. 
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III. Methods 
A. Study Setting 
This study was conducted at the Hunter Holmes McGuire Veterans Affairs (VA) medical 
center, Richmond, VA, using data from the outpatient anticoagulation clinic. The study 
protocol was approved by the Richmond Veterans Affairs institutional review board 
(IRB) and the Virginia Commonwealth University IRB in January 2011. Due to the 
retrospective nature of the study, informed consent was waived.  
 
B. Study Design and Patients 
This was a single-center, retrospective review of medical and pharmacy records of 
patients aged 65 years and above, who received a prescription of warfarin and either 
amoxicillin, azithromycin, cephalexin, ciprofloxacin, levofloxacin or moxifloxacin, 
concomitantly from January 1, 2003 to March 1, 2011. Patients that were included were 
aged 65 years and above and were on stable warfarin therapy, defined as pre-antibiotic 
INR values within ± 0.2 of recommended therapeutic INR range during the 4-week 
period before the antibiotic start date. This would eliminate patients with fluctuating INR 
values. In the presence of 2 or more pre-antibiotic INR values, all INR values were 
recorded. Patients must also have had at least one INR value recorded during their 
antibiotic therapy or during the 14-day period after discontinuation of the antibiotic (i.e. 
post-antibiotic INR) in order to be included. In addition, patients must have had a 
prescription of the antibiotic for 3 days or more in order to be included. 
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Patients were excluded if there was a change in their warfarin dose from the date their 
pre-antibiotic INR was recorded to the date of starting their antibiotic prescription or if 
there was a change in the patient’s warfarin dose after the antibiotic start date and before 
the post-antibiotic INR value was recorded. Patients were excluded if they did not have 
an anticoagulation clinic note before and after the period of starting the antibiotic. 
Without a clinic note it would not be possible to ascertain whether patients were on stable 
warfarin therapy, were compliant to therapy or to gather information on other 
concomitant interacting medications that the patient may have been prescribed. Patients 
that were not compliant to warfarin therapy were excluded since non-compliance may 
lead to fluctuating INR values. Patients undergoing a dental procedure were not included 
because antibiotics are usually given prophylactically for these patients and may be 
prescribed as a one-time course of one day. These patients may also not be the same as 
the other study patients with an active infection. Patients receiving enoxaparin (LMWH) 
concomitantly with warfarin were excluded since this may further complicate 
anticoagulant activity. Finally, patients were excluded if they received a prescription for 
other potentially interacting medications during the period from the last pre-antibiotic 
INR measurement and the first post-antibiotic INR measurement. The potentially 
interacting medications that patients were screened for in this study included, 
amiodarone, metronidazole, trimethoprim-sulfamethoxazole, carbamazepine, phenytoin, 
fluconazole, ketoconazole, rifampin, isoniazid, prednisone and phenobarbital, since they 
are known to have a well-documented interaction with warfarin.(4) Patients newly 
initiated on amiodarone were not included since a warfarin dose reduction of 20-50% is 
generally done for these patients.  
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      C. Data Collection 
A list of patients meeting the inclusion criteria was electronically generated. The 
electronic medical recording system of the VA, known as the Computerized Patient 
Record System (CPRS), was used to collect patients’ demographic data, such as age, sex 
and race; prescription data such as warfarin and antibiotics dose, duration of use, and 
indications for use, warfarin dose adjustments, vitamin K administration; laboratory data 
such as target INR range, pre- and post-antibiotic INR values and other medical data such 
as number of concomitant medications and disease conditions, interacting medications 
(as listed above), bleeding events, hospitalizations, or emergency department visits. Data 
were entered and stored in a secure, password-protected computer.  
 
D. Outcome Measures 
The outcomes of interest for the primary analysis were the post-antibiotic INR values. 
Pre-antibiotic INR values were collected during the 4-week period before start of the 
antibiotics. All INR values during this period were recorded as long as they were within ± 
0.2 of the therapeutic INR range. Thus pre-antibiotic INR values were defined as the 
most recent INR values collected in the 4-week period before start of the antibiotic 
therapy. Post-antibiotic INR values were collected during the duration of use of the 
antibiotic or during the 14-day period following the discontinuation of antibiotic therapy. 
All available INR values during this period were recorded. Thus post-antibiotic INR 
values were defined as all INR values available after start of the antibiotic up to 14-days 
after discontinuation of the antibiotic therapy.  
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The secondary outcomes of interest were percentage of patients whose warfarin dose was 
adjusted (reduced or withheld); INR > therapeutic; INR increase >1, or INR increase > 2; 
absolute INR ≥ 4, or absolute INR ≥ 5; vitamin K administration; minor or major 
bleeding events; hospitalizations or emergency department visits. Cephalexin was chosen 
as a comparator drug to compare the percentages of patients with the above secondary 
outcomes of over-anticoagulation to the percentages of patients with the above outcomes 
for the amoxicillin, azithromycin, ciprofloxacin, levofloxacin and moxifloxacin groups. 
There were several reasons for choice of cephalexin as a comparator drug. More than 
90% of cephalexin is excreted unchanged renally and does not undergo metabolism via 
hepatic CYP2C9 pathways.(18) Thus pharmacologically cephalexin would not have the 
potential to interact with warfarin since it would not inhibit warfarin metabolism. 
According to the consensus of clinical opinion, cephalexin is not known to interact with 
warfarin.(19) Standard drug-drug interaction compendia and systematic reviews of 
warfarin drug interactions do not classify cephalexin as a warfarin-interacting 
medication.(4) One way of reducing confounding by indication is to use a control drug 
that has similar prescription indications as the other antibiotics. Cephalexin has similar 
indications as the other antibiotics in this study.(20) Cephalexin is used to treat 
respiratory tract infections, otitis media, skin and skin structure infections, bone infection 
and genitourinary tract infections. Thus use of a control drug with similar indications will 
help to ensure that all patients being compared have an active infection. 
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E. Statistical Analysis 
Continuous data are presented using means, SD and ranges. Categorical baseline data are 
presented as frequencies and percentages. Mixed-effects repeated measures ANOVA 
model was used to determine the effect of antibiotics on the mean change in patient’s 
INR over time. Statistical significance was defined at an alpha level of 0.05. The changes 
in INR values between time point 2 (i.e. pre-antibiotic INR 2) and time point 3 (i.e. post-
antibiotic INR 1) for each antibiotic were of interest (i.e. 6 comparisons). In addition, the 
change in INR values at time points 3 (i.e. post-antibiotic INR 1) between each antibiotic 
was also of interest (i.e.15 comparisons). Thus there were a total of 21 comparisons of 
interest. A Bonferroni adjustment of the alpha level was done to account for these 
multiple comparisons (adjusted alpha = 0.05/21 = 0.0023). 
 
A chi-square test or Fisher’s exact test, where appropriate, was done to test whether there 
was an association between the type of antibiotic and the secondary outcomes of over-
anticoagulation. The percentage of patients with the secondary outcomes of over-
anticoagulation i.e., INR increase ≥ therapeutic, INR increase ≥ 1, INR increase ≥ 2, 
absolute INR ≥ 4, absolute INR ≥ 5 and warfarin dose adjustment, with azithromycin, 
amoxicillin, ciprofloxacin, levofloxacin and moxifloxacin were compared with those on 
cephalexin. All analyses were done using SAS 9.2. 
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      IV. Results 
A total of 205 patients received 364 prescriptions for the antibiotics of interest 
concomitantly while on warfarin therapy, such that there were 96 prescriptions for 
amoxicillin, 73 prescriptions for azithromycin, 49 prescriptions for cephalexin, 64 
prescriptions for ciprofloxacin, 28 prescriptions for levofloxacin and 54 prescriptions for 
moxifloxacin during the time frame of the study. The mean age of the patients was 75.7 
(SD = 6.7) years and the median age was 75.5 (interquartile range = 70-81) years. The 
mean pre-antibiotic INR values for patients ranged from 2.3 to 2.5 (SD = 0.4- 0.5) across 
the six antibiotics. The baseline demographic characteristics of the patients are shown in 
Table 1. The population primarily consisted of white males and the two most common 
indications for warfarin use were atrial fibrillation and deep vein thrombosis. 
 
The ANOVA model indicated that there was a significant interaction between antibiotic 
and time (F (15, 358) = 1.9; p-value = 0.0221). These results indicate that the pattern of 
INR changes for the 6 antibiotics are significantly different across time. The mean change 
in INR from pre-antibiotic INR value 2 to post-antibiotic INR value 1, for each of the six 
antibiotics is shown in Table 2. This mean INR increase was significant for amoxicillin 
(0.31 ± 0.10, p=0.0019), azithromycin (0.60 ± 0.11, p <0.0001), ciprofloxacin (0.38 ± 
0.12, p=0.002), levofloxacin (0.75 ± 0.18, p <0.0001) and moxifloxacin (0.70 ± 0.13, p < 
0.0001). There was no significant increase in INR for cephalexin between time point 2 
and 3 (p=0.2807). This trend of change in INR values over time for each antibiotic is 
shown in Figure 1. Additionally, at time point 3 there were no significant differences in 
post-antibiotic INR values between the six different antibiotics. 
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The frequency and percentages of patients experiencing the secondary outcomes of over-
anticoagulation for each antibiotic group are shown in Table 2. The percentage of 
patients who had a warfarin dose adjustment (either withheld or reduced) was the highest 
for levofloxacin (25%), followed by moxifloxacin (24%), ciprofloxacin (17%) and 
azithromycin (12%). The Fisher’s exact test indicated that these percentages were 
significantly higher (p<0.05) for the fluoroquinolone antibiotics and azithromycin as 
compared to cephalexin (2%). The percentages and p-values were computed from the 
Fisher’s exact test using a separate 2x2 table for the comparison of each antibiotic group 
with the cephalexin group. For increase in INR above therapeutic range, the percentage 
of patients was significantly higher (p<0.05) for azithromycin (41%), levofloxacin (46%) 
and moxifloxacin (40%) as compared to cephalexin (16%). For an increase in INR by 
more than one point, the percentages of patients were significantly higher (p<0.05) for 
azithromycin (23%), ciprofloxacin (20%), levofloxacin (36%) and moxifloxacin (31%) as 
compared to cephalexin (4%). Finally, the percentage of patients with absolute INR ≥ 4 
was significantly higher (p<0.05) for the moxifloxacin group (15%) as compared to 
cephalexin (2%). There were no reports of major or minor bleeding events; 
hospitalizations or emergency department visits during concomitant warfarin antibiotic 
therapy. 
 
Additional post-hoc analyses were done to explain the effect of infection and the effect of 
increasing age on INR changes. To test for the effect of infection, mean change in INR 
from pre- to post-antibiotic use was determined separately by type of infection for all 
fluoroquinolones (ciprofloxacin, levofloxacin and moxifloxacin) and azithromycin. 
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(There were not sufficient patients for this analysis in the other antibiotic groups). The 
results of the repeated-measures ANOVA model indicated that for the fluoroquinolone 
group the mean increase from pre- to post-antibiotic INR was significant for all patients 
with a lower respiratory tract infection (0.8 ± 0.2; p = 0.0007) or a urinary tract infection 
(0.4 ± 0.1; p=0.0132) but was not significant for patients with a skin or soft tissue 
infection (0.5 ± 0.3; p =0.3870). For the azithromycin group the mean increase in INR 
was significant for patients with lower respiratory infections (0.7 ± 0.1; p <0.0001) and 
for those with upper respiratory infection (0.5 ± 0.1; p=0.0103). These results are shown 
in Table 3. 
 
Furthermore, to test for the effect of increasing age, the mean change in post-antibiotic 
INR were compared for the lower age quartile (i.e. patients aged 65-70 years) and upper 
age quartile (i.e. patients aged ≥ 81 years). For the first recorded mean post-antibiotic 
INR value there was no difference between the lower and upper quartiles of age (mean 
difference in INR=0.10 ± 0.13; p=0.3783). However, for the second recorded post-
antibiotic INR values, the mean INR value was significantly greater in the upper age 
quartile, i.e. patients aged ≥ 81 years, as compared to the lower age quartile, i.e. patients 
aged 65-70 years (mean difference in INR= 0.70 ± 0.25; p=0.0036). These results are 
shown in Table 4. Additionally, Table 5 provides details of patients with an INR ≥ 4, 
such as dosage and duration of antibiotic, type of infection, pre- and post-antibiotic INR 
and warfarin dose adjustments, after start of the antibiotic. 
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Table 1: Baseline demographic and clinical characteristics of study patients 
 
Characteristic 
Amoxicillin 
(N = 96) 
Azithromycin 
(N = 73) 
Cephalexin 
(N = 49) 
Ciprofloxacin 
(N = 64) 
Levofloxacin 
(N = 28) 
Moxifloxacin 
(N = 54) 
Mean (SD) 
Mean Age, years 
Median (IQR), years 
75.3 (6.6) 
74 (71-80) 
74.1 (6.7) 
74 (68-80) 
75.4 (6.1) 
75 (70-79) 
76.6 (6.5) 
77.5 (71-81) 
79 (7.2) 
82 (73-85) 
75.7 (6.6) 
76 (71-81) 
Pre-antibiotic INR 1 
Pre-antibiotic INR 2 
2.4 ± 0.4 
2.4 ± 0.4 
2.4 ± 0.5 
2.4 ± 0.4 
2.4 ± 0.4 
2.5 ± 0.4 
2.3 ± 0.4 
2.5 ± 0.4 
2.4 ± 0.4 
2.4 ± 0.4 
2.4 ± 0.5 
2.3 ± 0.4 
Duration of antibiotic use, days 10 (2) 6 (3) 11 (6) 14 (10) 9 (6) 9 (5) 
Total number of medications 11 (4) 11 (4) 11 (4) 11 (5) 12 (5) 12 (5) 
Total number of disease conditions 12 (5) 12 (5) 12 (6) 12 (5) 13 (5) 13 (6) 
No (%) of Patients 
Males 95 (99) 73 (100) 48 (98) 63 (98) 28 (100) 53 (98) 
Race (white) 78 (81) 53 (73) 38 (78) 42 (66) 16 (57) 40 (74) 
Indication for warfarin use 
    Atrial fibrillation/ Atrial flutter 
    DVT/ PE 
    Mechanical valve replacement 
    Other 
 
75 (78) 
13 (14) 
2 (2) 
6 (6) 
 
63 (86) 
10 (14) 
- 
- 
 
39 (80) 
6 (12) 
2 (4) 
2 (4) 
 
47 (74) 
5 (8) 
2 (3) 
10 (16) 
 
19 (68) 
8 (29) 
1 (4) 
- 
 
46 (85) 
5 (9) 
1 (2) 
2 (4) 
Indication for antibiotic use 
    Lower respiratory infections (LRI) 
    Upper respiratory infections (URI) 
    Urinary tract infections (UTI) 
    Skin & soft tissue infection (SSTI) 
    Other 
 
16 (17) 
19 (20) 
17 (18) 
33 (34) 
11 (12) 
 
35 (48) 
35 (48) 
- 
1 (1) 
2 (3) 
 
- 
1 (2) 
3 (6) 
40 (82) 
5 (10) 
 
1 (2) 
1 (2) 
43 (67) 
2 (3) 
17 (27) 
 
4 (14) 
1 (4) 
18 (64) 
3 (11) 
2 (7) 
 
34 (63) 
12 (22) 
2 (4) 
6 (11) 
- 
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Table 2: International normalized ratio changes and secondary outcomes of over-anticoagulation 
 
Variable  
Amoxicillin 
(N = 96) 
Azithromycin 
(N = 73) 
Cephalexin 
(N = 49) 
Ciprofloxacin 
(N = 64) 
Levofloxacin 
(N = 28) 
Moxifloxacin 
(N = 54) 
INR change (from pre-antibiotic 
INR 2 to post-antibiotic INR 1) 
    Mean (SE) 
 
 
0.31 ± 0.10* 
 
 
0.60 ± 0.11* 
 
 
0.15 ± 0.14 
 
 
0.38 ± 0.12* 
 
 
0.75 ± 0.18* 
 
 
0.70 ± 0.13* 
No. (%) of patients 
Intervention 
    Warfarin dose withheld 
 
9 (9) 
 
9 (12)** 
 
1 (2) 
 
11 (17)† 
 
7 (25)† 
 
13 (24)† 
Secondary outcomes of over-
anticoagulation  
    INR > therapeutic 
    INR increase > 1 
    INR increase > 2 
    Absolute INR ≥ 4 
    Absolute INR ≥ 5 
 
 
25 (26) 
15 (16) 
3 (3) 
6 (6) 
1 (1) 
 
 
30 (41)† 
17 (23)† 
5 (7) 
7 (10) 
- 
 
 
8 (16) 
2 (4) 
1 (2) 
1 (2) 
- 
 
 
20 (31) 
13 (20)** 
4 (6) 
5 (8) 
1 (2) 
 
 
13 (46)† 
10 (36)‡ 
2 (7) 
3 (11) 
1 (4) 
 
 
22 (40)† 
17 (31)‡ 
6 (11) 
8 (15)** 
- 
* p-value < 0.023 Bonferroni adjusted alpha-level 
** p-value < 0.05 versus cephalexin 
†  p-value  < 0.01 versus cephalexin 
‡  p-value < 0.0001 versus cephalexin	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Figure 1: Least squares means plot of change in INR values over time for different 
antibiotics 
 
(INR = International Normalized Ratio) 
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Table 3: International normalized ratio changes by type of indication for antibiotic 
use 
 
 
 
Type of Infection 
INR change, from pre-antibiotic INR 2 
to post-antibiotic INR 1 
Fluoroquinolones 
(N = 146) 
Azithromycin 
(N = 73) 
1. Lower respiratory tract infection (LRI) 0.8 ± 0.2* 0.7 ± 0.1* 
2. Upper respiratory tract infection (URI) - 0.5 ± 0.1* 
3. Urinary tract infection (UTI) 0.4 ± 0.1* - 
4. Skin and soft tissue infection (SSTI) 0.5 ± 0.3 - 
*Denotes significant increase in INR from pre-antibiotic INR 2 to post-antibiotic INR 
from the ANOVA model 
 
Table 4: Mean INR values and change in INR values for subjects in the upper and 
lower age quartiles 
 
 N Mean INR  
(65-70 yrs) 
N Mean INR 
(≥ 81 yrs) 
Difference 
in INR  
p-value 
 
Pre-antibiotic INR 1 37 2.3 ± 0.4 37 2.5 ± 0.4 0.20 ± 0.10 0.1198 
Pre-antibiotic INR 2 95 2.4 ± 0.4 98 2.4 ± 0.4 0.02 ± 0.06 0.7385 
Post-antibiotic INR 1 95 2.9 ± 0.9 98 3.0 ± 1.0 0.10 ± 0.13 0.3783 
Post-antibiotic INR 2 10 2.7 ± 0.6 18 3.5 ± 0.8 0.70 ± 0.25 0.0036* 
* Denotes that the upper age quartile (i.e. ≥ 81 years) has significantly greater mean INR 
values at time point 4 as compared to lower age quartile (i.e. 65-70 years) at a Bonferroni 
adjusted significance level of 0.0125. 	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Table 5: Details of patients with an absolute INR ≥ 4 after antibiotic use 
Age  
(yrs), 
sex 
Warfarin 
Indication Antibiotic 
Antibiotic Dosage 
and Duration 
Antibiotic  
Indication 
Pre-
antibiotic 
INR 
Post-
antibiotic 
INR 
Days after 
starting 
antibiotic 
Warfarin 
held/ 
reduced 
 
83, M Afib Moxifloxacin 400mg qd x 14 days Pneumonia 2.4 4.6, 5.5 16 Yes 
84, M Afib Moxifloxacin 400mg qd x 8 days Pneumonia 2.7, 2.6 4.6 14 Yes 
67, M DVT/ PE Cephalexin 
500mg four times x 
7 days Cellulitis 2.4, 2.9 5.4 16 Yes 
69, M DVT/ PE Levofloxacin 250mg qd x 7 days UTI 2.8 4.3 24 Yes 
82, M Afib Moxifloxacin 400mg x 14 days Skin infection 1.9, 2 5.5 11 Yes 
66, M Afib Moxifloxacin 400mg qd x 5 days Pneumonia 3.2, 2.9 6.4 3 Yes 
65, M Afib Moxifloxacin 400mg qd x 7 days Pneumonia 1.7, 1.8 5.4 7 Yes 
76, M Afib Azithromycin 
500mg x 1 day, 
250mg x 4 days Bronchitis 1.7 4.3 11 Yes 
69, M Afib Ciprofloxacin 750mg qd x 10 days Prostatitis 2.8 5.4 9 Yes 
85, M Afib Levofloxacin 250mg qd x 7 days UTI 1.7 4.1 6 Yes 
85, M Aflutter Moxifloxacin 400mg qd x 10 days Pneumonia  1.7 4.0 13 Yes 
69, M Afib Azithromycin 
500mg x 1 day, 
250mg x 4 days Cough 2.6 5.7 17 Yes 
83, M MVR Ciprofloxacin 500mg bd x 30 days 
Prostrate 
cancer 3.3 4.9 16 Yes 
77, M Afib Azithromycin 
500mg x 1 day, 
250mg x 4 days Bronchitis 2.8, 3.2 4.1 4 Yes 
74, M Afib Azithromycin 
500mg x 1 day, 
250mg x 4 days Congestion 
2.7, 3.0 
1.8 4.1 3 Yes 
73, M Afib Moxifloxacin 400mg qd x 19 days SOB, cough 2.5, 3.2 4.2 18 Yes 
80, M Afib Amoxicillin 500mg tid x 7 days Wound care 3.1 4.3 4 No 
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Age  
(yrs), 
sex 
 
 
Warfarin 
Indication 
 
 
Antibiotic 
 
 
Antibiotic Dosage 
and Duration 
 
 
Antibiotic  
Indication 
 
 
Pre-
antibiotic 
INR 
 
 
Post-
antibiotic 
INR 
 
 
Days after 
starting 
antibiotic 
 
 
Warfarin 
held/ 
reduced 
 
83, M Afib Moxifloxacin 400mg qd x 9 days Pneumonia  2.7, 2.3 4.2 3 Yes 
75, M Afib Moxifloxacin 400mg qd x 10 days 
Pneumonia, 
cough, SOB 1.7, 2 4.9 3 Yes 
82, M Afib Amoxicillin 875mg bd x 10 days Cellulitis 2.8 4.4 12 Yes 
83, M DVT/ PE Levofloxacin 500mg qd x 7 days Pneumonia 2.6 8.0 5 No 
71, M Afib Ciprofloxacin 500mg bd x 18 days Prostatitis 2.7 4.8 20 Yes 
68, M Afib Azithromycin 
500mg x 1 day, 
250mg x 4 days URI 3.0 4.8 8 Yes 
83, M DVT/ PE Azithromycin 
500mg x 1 day, 
250mg x 4 days 
Mild COPD, 
cough, sore 
throat 2.1 4.3 14 Yes 
71, M 
Cardiomyo
pathy Ciprofloxacin 250mg bd x 14 days 
Prostrate 
biopsy 2.4 4.2 5 Yes 
77, M Afib  Amoxicillin  250 mg tid x 10 days Pneumonia 2.2, 3.1 10.8, 6.6 3 Yes 
85, M Afib Levofloxacin 250 mg qd x 7 days UTI 2.7, 1.7 4.1, 4.5 3 Yes 
73, M Afib Levofloxacin  500 mg qd x 10 days Epididymitis 3.0, 3.1 4.3 14 Yes 
77, M Afib Azithromycin 
250mg bd x 1day; 
qd x 4days 
COPD 
exacerbation  2.1 4.3 12 No 
69, M AFib Amoxicillin  1 tab bd x 20 days 
Cold/ sinus 
infection 2.2, 3.0 5.0 15 Yes 
80, M Afib Amoxicillin  1 tb bd x 7 days 
Leg wound 
infection 3.1 4.3 4 Yes 
83, M Afib Moxifloxacin  400 mg qd x 14 days Pneumonia 2.4 4.2 5 Yes 	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V. Discussion 
The results of this study showed that amoxicillin, azithromycin and fluoroquinolone antibiotics 
such as ciprofloxacin, levofloxacin and moxifloxacin, lead to a significant increase in INR values 
post-antibiotic use in older patients, when taken concomitantly with warfarin. This increase in 
post-antibiotic INR did not lead to clinically significant outcomes of bleeding or hospitalization. 
However, warfarin dose adjustments due to an increase in post-antibiotic INR was required for 
approximately 20% of patients across the 3 groups of fluoroquinolone antibiotics. In addition, 
patients experienced other outcomes of over-anticoagulation such as increase in INR above 
therapeutic range and increase in INR by more than 1 point while taking fluoroquinolones and 
azithromycin concomitantly with warfarin. Details of patients with an INR ≥ 4 after start of the 
antibiotic have been included and almost all these patients had their warfarin dose withheld or 
reduced, which may have further prevented any bleeding outcomes. However, these were 
patients at a high risk of a hemorrhage, since the risk of serious hemorrhage increases at INR ≥ 
4.(21) Furthermore, patients taking fluoroquinolones with an indication for skin and soft tissue 
infections did not experience an increase in post-antibiotic INR, whereas patients with lower 
respiratory infections and urinary tract infections did experience an increase in INR with 
fluoroquinolones. These results suggest that type of infection may play a role in the increase in 
patient’s INR. A similar conclusion was made in a previous study, wherein the infection, or its 
sequelae (i.e. fever and reduced vitamin K intake and uptake) was suggested to increase the 
bleeding risk in patients receiving an anti-infective agent, since the ‘baseline’ bleeding risk for 
the patients was already elevated even before starting the anti-infective agent.(22)  
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Previously, four retrospective cohort studies have assessed the mean change in INR after 
administration of levofloxacin to patients on stable warfarin therapy, from which two studies 
found a significant increase in mean INR change,(23, 24) whereas the other two studies did 
not.(14, 16) There have been only three retrospective studies that have looked at the potential 
interaction between azithromycin and warfarin,(15, 17, 24)and two of these did not find any 
evidence for a significant interaction between warfarin and azithromycin.(17, 25) The sample 
size of these studies was limited with the largest study having a sample size of only 52 patients. 
Thus the power to detect a difference in the INR may have been low for most of the studies. The 
only study to have assessed the risk of bleeding with amoxicillin for patients on warfarin did not 
find an association between risk of hemorrhage and use of warfarin-amoxicillin or warfarin-
ampicillin combination. (26) 
 
Some strengths of this study may be noted. The mean age of patients that were included in this 
study was about 76 years. Thus the effect of warfarin-antibiotic interactions could be studied in 
older patients. This is important because the older population may be at higher risk of a drug 
interaction due to increased sensitivity in pharmacodynamic response to warfarin and reduced 
clearance of certain antibiotics such as fluoroquinolones.(6, 27) This was the only known study 
to have evaluated the effect on INR values separately for the lower and upper age quartiles. An 
age effect was seen such that patients aged ≥ 81 years had a significantly higher mean post-
antibiotic INR value as compared to patients in the lower age quartile. However, this comparison 
was based on fewer observations at the second post-antibiotic INR values. The internal validity 
of the study was enhanced by only including those patients who were on stable warfarin therapy 
before starting the antibiotic. Thus any increase in INR value after starting the antibiotic may 
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become apparent in such patients. Anticoagulation clinic notes made by the Veterans Affairs 
clinical pharmacists increases the validity of the findings since the possible reasons for a 
supratherapeutic INR are often recorded in the clinical notes. If the clinical pharmacist suspected 
that the supratherapeutic INR might be due to the antibiotic this would be noted and would thus 
corroborate the findings of this study. However, there may be a systematic reporting bias in this 
situation depending on the clinical pharmacist’s beliefs regarding the significance of the potential 
drug interaction. Due to this reason clinic notes were only regarded as providing additional but 
not definitive evidence. In addition, most patients receive almost all their health care at the VA 
and information on concomitant medications, dosage changes, coexisting disease conditions and 
health-care procedures is well documented in the patient’s electronic medical record. This 
provides additional information on potential confounding factors, unlike large population-level, 
health care databases. 
 
There were some limitations of this study given the retrospective nature of data collection. 
Changes in use of over-the-counter medications, herbal remedies and other vitamin supplements 
with a potential to interact with warfarin may not have been recorded in the patient’s medical 
records. Although dietary changes, medication changes and compliance with warfarin therapy 
are assessed during each patient visit, patient recall bias may be a potential limitation. For 
example, cranberry juice, which is recommended for the treatment of UTIs, may also interact 
with warfarin and its use may not be recorded for all patients. However, attempts to control for 
potential confounding factors such as use of warfarin interacting medications, fluctuating INR 
values, and patient noncompliance were made in the study design by excluding patients with 
these factors. Since the data for the study were obtained from an anticoagulation clinic at a 
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Veteran’s Affairs Medical Center, only antibiotics on the VA formulary were included. The 
results of this study are only generalizable to patients receiving routine monitoring in an 
anticoagulation clinic as compared to other models of anticoagulant care. Since warfarin dosage 
adjustments were done for patients with supratherapeutic INR values, it was not possible to 
ascertain whether supratherapeutic INR would have resulted in clinically significant outcomes of 
bleeding or hospitalization through this study. In a setting where patients are not as closely 
monitored, the outcomes of bleeding events may vary.  
 
Another possible limitation of the study is that several patients had only one pre- and post-
antibiotic INR value recorded. The presence of two or more pre- and post-antibiotic INR values 
for all patients would have further enhanced the internal validity of the study. However, the 
method of analysis chosen for this study was a repeated-effects mixed model ANOVA that does 
allow for missing data. In addition, the missing INR values were only for the pre-antibiotic INR 
1 values and for the last post-antibiotic INR 2 values, whereas the comparisons were only made 
from pre-antibiotic INR 2 to post-antibiotic INR 1. The time points at which pre- and post-
antibiotic INR values were recorded were not the same for all patients. For example, some 
patients may have a pre-antibiotic INR value recorded 10 days before starting the antibiotic and 
another patient may have a value recorded 2 days before starting the antibiotic. This may not be a 
major limitation since the sole purpose of recording pre-antibiotic INR values was to determine 
whether the patient was on stable warfarin therapy. However, post-antibiotic INR values were 
recorded within the pre-defined time frame of total duration of antibiotic use plus 14 days after 
completing the course of antibiotics. This time frame may have resulted in missing the drug 
interaction for some patients. As an attempt to increase the internal validity of the study, only 
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those patients on stable warfarin therapy before start of the antibiotic were included. Thus the 
results are not generalizable to those patients who may have fluctuating INR values or warfarin 
dosage adjustments being made before start of an antibiotic, as may be routinely seen in clinical 
practice. Finally, the aim of the study was to characterize warfarin-antibiotic interactions in older 
patients and a majority of the patients were white males, thus the results may not be entirely 
applicable to other patient populations. This may not be a big issue given that there have been no 
reports of gender differences in warfarin PK or PD. However, the prevalence of genetic 
polymorphisms for the enzymes that metabolize warfarin is higher in the non-white race and this 
may potentially have an effect on warfarin sensitivity in the non-white race. Due to the under-
representation of the non-white race we were unable to study this effect. 
 
      VI. Conclusion 
The results of this study provide evidence for an increase in patient’s INR post-antibiotic use that 
may lead to a warfarin dose adjustment in several patients, however there was no evidence for 
clinical outcomes of bleeding or hospitalization as a result of this increase in INR. These 
clinically significant outcomes of bleeding and hospitalization may have been prevented due to 
warfarin doses being held or reduced. Based on the results of this study a change in clinical 
practice such as empirical reduction of warfarin dose when antibiotics are prescribed 
concomitantly with warfarin may not be required. However, the results of bleeding outcomes 
may be different in a setting where patients are not monitored as closely as those in an outpatient 
anticoagulation clinic. Thus antibiotics may be prescribed to older adults on warfarin therapy as 
long as their INR is closely monitored, especially with fluoroquinolones, both during and after 
the course of antibiotic therapy. 
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CHAPTER 5 
DISCUSSION AND CONCLUSION 
 
I. Underuse of Warfarin in Nursing Home Residents 
The results of this cross-sectional analysis of a large nationally representative survey dataset 
showed that 54% of nursing home residents with atrial fibrillation, who had indications for 
warfarin use and no contraindications to warfarin use, did not receive anticoagulation therapy 
with either warfarin or antiplatelet agents such as aspirin or clopidogrel. The next few sections 
will outline possible reasons for the observed underuse of warfarin therapy with a focus on 
common barriers to warfarin use, barriers to successful implementation of evidence-based 
medicine in long-term care settings and tools that may be employed to evaluate risks and benefits 
of warfarin therapy in order to assist healthcare providers to identify ‘ideal’ candidates for 
anticoagulant therapy.  
 
A. Possible Explanations and Barriers to Prescribing Warfarin 
The rate of warfarin use observed in this study was found to be similar to the rates reported 
previously.(1-3) It was surprising to find that more than half the NH residents were not receiving 
suitable anticoagulation therapy even after excluding those with contraindications to warfarin use 
and those without indications to warfarin use. Even though some patients may have 
characteristics that would require them to be on an anticoagulant, other reasons such as patient 
refusal, patient noncompliance, an upcoming planned surgery and reduced life expectancy may 
result in the patient not receiving a prescription for an anticoagulant. In addition, there exist 
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several barriers to prescribing warfarin therapy, especially in older adults. The most commonly 
cited reason among physicians for not prescribing warfarin is the higher perceived risk of 
bleeding associated with warfarin.(4, 5) Increasing age has also been consistently identified as a 
barrier to anticoagulant therapy.(6) This was supported by one of the findings of this study, 
wherein residents aged 90 years or above were less likely to be prescribed warfarin. However, 
the older population is believed to have the greatest absolute reduction in stroke rates with 
warfarin therapy.(7) In addition, the prevalence of atrial fibrillation increases with advancing age 
such that atrial fibrillation was present in 6% of those aged 65-74 years, 12% in people aged 75-
84 and 16% in people aged 85 and over.(8) Other factors cited by physicians as challenges to 
managing warfarin therapy include, dealing with medications that interact with warfarin, 
maintaining patients within therapeutic range and making warfarin dose adjustments.(9) Risk of 
falls and dementia are also concerns physicians may have before initiating warfarin therapy.(10). 
Lack of reimbursement, time, facilities and/or expertise may be other possible reasons for which 
individual practitioners may not be willing to undertake anticoagulation monitoring.(11) 
Understanding barriers pertaining to warfarin use in NH residents is important since this would 
help to develop targeted interventions to address the issues of underuse of warfarin and other 
anti-platelet agents. 
 
Pharmacists-managed anticoagulation services have been shown to improve anticoagulation 
control, reduce bleeding and thromboembolic events and reduce rates of anticoagulation-related 
emergency department visits.(12, 13) Thus if lack of monitoring or poor monitoring of 
anticoagulant therapy in NH residents is a concern, the implementation of pharmacist-managed 
anticoagulation services in NHs may be a potential solution towards improving low rates of 
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warfarin use in this population. A study that evaluated physician attitudes towards use of 
anticoagulation services in NHs found that only about half the physicians surveyed were open to 
the idea of an anticoagulation service for their LTC residents.(9) One of the biggest concerns 
with use of such services was the potential increase in the cost of care for NH residents on 
warfarin. Thus future research may be done to evaluate the usefulness of anticoagulation services 
in LTC settings in reducing bleeding and thromboembolic events and cost-effectiveness of 
implementing such services. 
 
B. Barriers to Successful Implementation of Evidence-based Medicine in LTC setting 
Robust evidence exists for the use of anticoagulant or antiplatelet therapy as stroke prevention 
strategies in patients with atrial fibrillation.(14-16) Use of warfarin and other medications such 
as aspirin for secondary stroke prevention, have been shown to cause significant reductions in 
thromboembolic complications and significant reductions in morbidity and death.(17, 18) Due to 
the higher mean age and presence of several cardiovascular conditions that are considered to be 
risk factors for a stroke event, the NH population would seem to benefit the most from 
anticoagulant therapy for stroke prevention. However, the results of the study outlined in chapter 
3, show that a majority of NH residents with atrial fibrillation, with indications for warfarin use 
and without contraindications to warfarin, are not receiving anticoagulant therapy with either 
warfarin or with anti-platelet agents such as aspirin, clopidogrel or a combination of these 
medications. Thus the issue of importance here is the lack of use of evidence-based medicine for 
stroke prevention in NH residents. Several barriers to the successful implementation of evidence-
based medicine in long-term care residents have been identified previously.(19) For example, 
developing evidence-based guidelines for NH residents is a challenge due to the few trials that 
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include adults over 80 years of age. The evidence base for clinical management of frail nursing 
home residents with AF is limited in terms of risk-benefits with warfarin vs. aspirin and 
clopidogrel, since the mean age of patients in the ACTIVE-W trial was 70 years.(20) In addition, 
the decision to initiate a medication in a NH resident is not just dependent on the physician, but 
also on the patient, the residential care staff and the patient’s next of kin. While it is believed that 
NH residents may represent a ‘captive’ audience in a setting where close monitoring by trained 
clinical staff is possible on a daily basis and low-cost treatment options exists,(21) it is also 
important to note that the rates of staff attrition are very high in NHs.(22) This may further be 
complicated by multiple attending physicians, communication difficulties between physicians, 
the nursing staff and caregivers and physician visits that are only around once a month.(19) Since 
the day-to-day monitoring of residents is often dependent on caregivers and nurses, interventions 
to improve prescribing practices targeted solely towards physicians may not always suffice.(19) 
 
C. Evaluating Benefits and Risks to Warfarin Therapy in Oder Adults 
According to Quilliam and Lapane ‘non-treatment is not synonymous with under-treatment’.(23) 
This is because contraindications to warfarin may influence the decision to treat the patient. 
However, in our study patients with contraindications to warfarin use were not included. 
Furthermore, contraindications to warfarin therapy may not solely explain the high rates of 
underuse observed. Uncertainty regarding treatment risks and benefits may also contribute to the 
decision not to treat.(24) This sort of an uncertainty may be due to several factors. For example, 
the number and complexity of comorbid conditions, risks of drug interactions and adverse drug 
events with concomitant medications, frailty and higher risk of falls and dementia in NH 
residents may all be contributing to the uncertainty regarding the decision to treat with warfarin. 
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According to the Birmingham Atrial Fibrillation Treatment of the Aged Study (BAFTA),(25) 
and a meta-analysis,(26) the risk of bleeding with warfarin in older patients is no greater than 
that with aspirin. With advancing age, aspirin became progressively less effective and instead the 
risk of bleeding was found to increase.(26) Thus for patients older than 75 years, formal 
anticoagulation with warfarin may remain a preferred treatment option over aspirin. 
One way to determine whether an older patient is an appropriate candidate for anticoagulant 
therapy would be to evaluate the benefits and risks to warfarin therapy. This may be done 
through the combined use of clinical prediction rules for stroke and bleeding risk schemes in 
order to identify patients with atrial fibrillation who are likely to benefit from anticoagulant 
therapy and less likely to experience an adverse bleeding outcome. A patient’s stroke risk may be 
quantified by using one of the many available stroke risk stratification schemes such as 
CHADS2,(27) Framingham,(28) NICE guidelines,(29) ACC/AHA/ESC guidelines,(16) ACCP 
guidelines,(30) CHA2DS2-VASc(31) and the Rietbrock modified CHADS2 scheme.(32) A recent 
study that conducted a comprehensive assessment of these seven stroke risk stratification 
schemes in older people with atrial fibrillation, has demonstrated limited ability of these risk 
schemes to accurately predict stroke in older people.(33) The CHADS2 and CHA2DS2-VASc 
scores performed the best, yet only had a C statistic of 0.60 for their predictive ability. Based on 
these results the authors made a pragmatic recommendation for clinicians to classify all patients 
over 75 years as being at a high stroke risk and provide them with anticoagulant therapy until 
better tools are available for older adults. Meanwhile these risk scores may be used in those 
under 75 years. 
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Several bleeding prediction models are available to estimate the risk for major bleeding during 
anticoagulation therapy. Three bleeding risk schemes that have been developed and validated to 
quantify the bleeding risk in patients with atrial fibrillation are known as the Outpatient Bleeding 
Risk Index (OBRI),(34) HEMORR2HAGES score,(35) and the more recently developed HAS-
BLED score.(36) Since perceived risk of bleeding may be contributing to underuse of 
anticoagulant therapy, use of these bleeding prediction models to quantify the patient’s bleeding 
risk may aid in patient selection for anticoagulant therapy. Furthermore, benefits and risks should 
be evaluated taking patient preferences into consideration. Even if the decision to initiate 
warfarin therapy has been made after careful evaluation of risks and benefits in an individual 
patient, the importance of routinely monitoring warfarin therapy can never be replaced.  
 
II. Warfarin-Antibiotic Interactions 
The results of the warfarin-antibiotic research study in this dissertation suggested that there is an 
increase in the patient’s INR value as a result of concomitant use of warfarin with antibiotics 
such as amoxicillin, azithromycin and fluoroquinolones, such as ciprofloxacin, levofloxacin and 
moxifloxacin. This increase in INR did not lead to clinically significant outcomes such as 
bleeding and hospitalization, but patients did experience an increase in outcomes of over-
anticoagulation, such as INR values outside the therapeutic range. The implications of the study 
results are that empirical reduction of warfarin dose may not be required when these antibiotics 
are prescribed concomitantly with warfarin; however, it would be advisable to closely monitor 
patients during concomitant use of warfarin and antibiotics, and to adjust the warfarin dose as 
required. Healthcare providers may also need to be aware of this potential interaction between 
warfarin and antibiotics, especially in older patients, and the effect that infection or the 
	   130	  
accompanying inflammatory process may have on warfarin metabolism. In the following section 
we shall discuss possible explanations for the results of this study and the difficulties with 
managing warfarin-drug interactions in older adults. 
 
A. Possible Explanations of Study Results 
The primary outcome of change in patient’s INR as a result of warfarin-antibiotic interactions is 
an important outcome to consider since the increased risk of hemorrhagic complications as a 
result of increasing or fluctuating INR values has been well established previously.(37) Even 
though this increase in INR values did not result in bleeding events, the knowledge that 
concomitant use of warfarin-antibiotics led to fluctuating INR values is still important since it 
may interfere with the routine care and monitoring of patients on warfarin therapy. Maintaining 
the patient’s INR between 2.0-3.0 is crucial to attain warfarin efficacy while minimizing the risk 
of bleeding. A target INR greater than 3.0 as compared to that between 2.0-3.0, doubles the 
frequency of major bleeding events.(38) In addition, anti-coagulated patients, regardless of INR, 
are still at bleeding risk. Furthermore, warfarin dose adjustments made by the clinical 
pharmacists at the VA anticoagulation clinic, as a result of supratherapeutic INR values, may 
have resulted in prevention of bleeding events.  
 
The effect that the underlying infection may have on warfarin-antibiotic interactions is also an 
important factor to consider. Cephalexin was the only antibiotic that did not lead to a significant 
increase in the patient’s INR post-antibiotic use in this study. One possible reason for this may 
be that majority of the patient’s that were prescribed cephalexin had an indication for a skin or 
soft tissue infection. During a respiratory infection such pneumonia, there tends to be 
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accompanying sequelae such as fever and reduced vitamin K intake, which may increase the 
severity of the respiratory infection. However, during a skin infection this is rarely the case. 
While a formal analysis for the effect of infection was not done in this study, a post-hoc analysis 
revealed a trend for the role of infection. There was no significant increase in the patient’s INR 
values when fluoroquinolones were prescribed for skin and soft tissue infections, but the increase 
in post-antibiotic INR values was significant when fluoroquinolones were prescribed for lower 
respiratory infections and urinary tract infections. Another method to evaluate the effect of 
infection on patient’s INR while on warfarin therapy would be via a prospective study wherein 
infected patients would have to be denied treatment with an antibiotic. Since this is not feasible 
or ethical, healthcare providers should be aware of the potential role of infection in warfarin-drug 
interactions. 
 
B. Difficulties with Managing Drug Interactions in Older Adults 
Since antibiotics are usually prescribed for a short course of therapy, it may be possible that a 
patient is on antibiotics without the knowledge of all of their healthcare providers. Although this 
may not be a problem at the VA since patients get most of their prescriptions filled at the VA 
pharmacy and patients enrolled in the anticoagulation clinic are routinely evaluated for any 
additions or changes in drug therapy, patients across all healthcare settings should be encouraged 
to inform their provider about all courses of antibiotic therapy.  
 
Another important issue with warfarin management, especially in NH residents, is the problem 
of poor information flow. There have been reported cases wherein a telephone call may have 
been made to a physician about a resident with a urinary tract infection without noting the use of 
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warfarin in the resident.(39) This would normally result in an order for an antibiotic that may 
interact with warfarin and thus result in an elevated risk of bleeding for the resident. While this 
may not be a problem in a healthcare setting such as the VA, where most of the patient’s 
healthcare records are available electronically, it may pose a problem for older patients seeing 
multiple providers or in a NH setting with a lack of provider-to-provider communication. 
Provider-to-provider communication may be improved via alerts in the electronic-health record 
(EHR) systems. The success of an EHR-based Warfarin/Antibiotic Rule in reducing over-
anticoagulation and adverse outcomes has been tested previously in a case study.(40) Currently 
there is no decision-support tool in the VA’s electronic recording system to ‘alert’ providers 
against the prescription of these antibiotics for patients on warfarin, and based on the results of 
this study, there may not be a need to implement such a system for patients who are closely 
followed by an anticoagulation clinic.  
 
III. Relationship Between Under-prescribing and Polypharmacy 
There may be a possible relationship between under-treatment with medications and 
polypharmacy in older adults. In a study of 154 geriatric out-patients, polypharmacy, defined as 
the use of 5 or more medications, was present in 61% from which 43% of these patients were 
undertreated for a disease for which drug therapy was indicated.(30) In contrast to 43% of 
patients with polypharmacy that were under-treated, only 13.5% of patients using 4 or less drugs 
were under-treated (adjusted OR = 4.8, 95% CI = 2.0 – 11.2), suggesting that there is a 
relationship between polypharmacy and under-treatment. Possible reasons for this relationship 
may be that physicians are cautious while prescribing multiple medications to patients on 
complex drug regimens due to fear of adverse drug reactions, interactions and poor compliance. 
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In this dissertation the issues of underuse of warfarin and warfarin-drug interactions in older 
adults were highlighted. Both of these are important issues in older adults and they may also be 
related in some way. Warfarin is known to interact with many medications and due to this reason 
physicians may be cautious while prescribing warfarin to a patient who already has a complex 
medication regimen.  
 
 
III. Role of Newly Approved Oral Anticoagulants: Dabigatran and Rivaroxaban 
Since warfarin has a narrow therapeutic index, inter-individual variability in dose response, 
numerous drug and food interactions, routine monitoring and dose adjustments are required for a 
patient on warfarin. Due to these reasons the risk of under-treatment with warfarin is also very 
high. As a result of challenges associated with warfarin management several attempts have been 
made to develop newer and safer oral anticoagulants. The direct thrombin inhibitor, dabigatran 
gained FDA approval for prevention of stroke in patients with AF in September 2010 and the 
direct factor Xa inhibitor, rivaroxaban recently gained approval for use in patients with AF in 
November 2011, based on their demonstrated efficacy in phase 3 clinical trials towards 
prevention of stroke and systemic embolism in patients with AF.(41, 42) In addition to their 
recommended use in patients with AF, dabigatran and rivaroxaban have demonstrated efficacy 
and safety for use in venous thromboembolism prophylaxis in orthopedic surgery patients.(43) A 
lot of emphasis has been placed on the advantages of dabigatran and rivaroxaban in terms of 
reduced patient monitoring required, administration at fixed doses and renal excretion of these 
medications.(44) However, a point of caution is that the efficacy and safety of these medications 
have not been evaluated in patients with renal failure.(44) This may have important implications 
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for use in patients with moderate to severe renal insufficiency and especially for the older patient 
population that is known to have a decline in renal function. In addition, there is lack of a widely 
available antidote to these medications in case of a severe bleeding event or an emergency 
situation.(45) Further information is required from post-approval studies regarding the 
effectiveness of the newer oral anticoagulants and appropriate monitoring methods in the older 
adult population, especially frail nursing home residents. As long as caution is exercised while 
prescribing these medications during daily practice, they may still serve as alternate treatment 
options for patients with a high-risk profile for stroke but with contraindications to 
anticoagulation with warfarin. On the other hand switching a NH resident from stable warfarin 
therapy to the newer anticoagulants may not be necessary given the established benefits of 
warfarin for stroke prevention and lack of information on use of these newer agents for patients 
with mechanical heart values or other indications. Furthermore, in certain situations a monitored 
anticoagulant such as warfarin may be preferred. For example, as long as warfarin is not 
contraindicated, due to the available methods of monitoring patients on warfarin, it may be a 
preferred anticoagulant for NH residents, for older patients with multiple co-morbid conditions 
and for patients using multiple medications that have a potential to interact with the 
anticoagulant. The ability to monitor the patient in such situations may be a more attractive 
option for the healthcare provider. 
 
In terms of drug interactions with the newer anticoagulants, there is limited information about 
potentially interacting medications and strategies to manage these interactions. Since dabigatran 
is not metabolized by the CYP450 enzyme system, it appears to have the lowest drug interaction 
potential, whereas rivaroxaban is partly metabolized by CYP3A4. (46) A recent review article 
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has summarized some of the recognized food and drug interactions with the newer oral 
anticoagulants,(43) However, the data for most of these drug interactions were obtained from 
animal models or healthy subjects, suggesting that there is a lack of clinical experience with new 
oral anticoagulants and hence lack of information on clinical significance of drug interactions 
with these agents. Furthermore, patients with severe liver and renal diseases were excluded from 
the clinical trials of dabigatran and rivaroxaban.(43) Thus due to altered metabolic capacity in 
case of hepatic or renal diseases, or for older patients with hepatic or renal function decline, the 
pharmacokinetics and pharmacodynamics of new oral anticoagulants may be affected, and as a 
result the potential for a drug interaction may be augmented.(43) Due to a lack of reliable 
monitoring parameters, management of drug interactions with dabigatran and rivaroxaban may 
be further complicated. 
 
V. Conclusions and Future Research 
The research underlying this dissertation highlights two important medication-related problems 
in older adults, that is, under-treatment and drug-drug interactions, using a high-risk drug such as 
warfarin as the example. The first project highlighted the high rates of underuse of warfarin in 
nursing home residents with atrial fibrillation along with the factors associated with warfarin use, 
such as increasing age, race, stroke and bleeding risk factors. The second project provided 
evidence for an increase in anticoagulant activity for warfarin, as measured by the patient’s 
international normalized ratio (INR), when antibiotics such as fluoroquinolones, azithromycin 
and amoxicillin were used concomitantly. While the currently available research on warfarin 
underuse and warfarin-antibiotic interactions has been conducted across the entire adult 
population, the research work undertaken in this dissertation represents the evidence for 
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underuse and drug interactions specifically for the older adult population, which is the population 
that tends to have the highest prevalence of conditions for which warfarin is indicated.  
 
Drug interactions have been designated as a drug safety measure by the Center for Medicare and 
Medicaid Services (CMS) and several quality improvement organizations throughout the nation 
have invested time and efforts in reducing warfarin-drug interactions, including warfarin-
antibiotic interactions as part of CMS’s drug safety initiative. Thus warfarin-drug interactions is 
a medication-related issue that is given national importance and the results of this study shed 
light on the clinical significance of warfarin-antibiotic interactions in the older adult population 
from an anticoagulation clinic. 
 
There remains room for future research to determine barriers to anticoagulation prescribing for 
NH residents and developing targeted interventions to increase rates of anticoagulation. The role 
of newly approved anticoagulants, dabigatran and rivaroxaban, in influencing the patterns of 
anticoagulation in NH settings remains to be determined. While warfarin-antibiotics may be 
safely prescribed to older adults as long as their INR is being frequently monitored, the safety of 
warfarin-antibiotic interactions in other models of anticoagulation care, such as home based care 
or the usual care model remains to be ascertained.  
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APPENDIX A 
List of validated ICD-9 codes used to identify diseases and conditions of 
interest 
Disease/ conditions of 
interest 
ICD-9 codes 
Atrial fibrillation 427.31 
Congestive heart failure 428, 398, 402, 404 
Hypertension 401-405, 437 
Diabetes 250 
Previous stroke/ TIA 434-436 
Coronary heart disease 410-414, 429, V45 
Valvular heart disease or 
valve replcement 
394- 398, 424, V42, V43 
DVT/ arterial peripheral 
embolus 
415, 444, 445, 451, 453 
Hemorrhagic tendencies 286- 287 
Recent surgery Sepsis (038, 020, 790, 117, 112), cardiac catheterization (37), 
cardiac surgery [coronary artery bypass graft surgery (36), valve 
repair (35)] 
History of GI bleeding 531-534, 578 
Dementia 290 
Myocardial infarction 410  
Chronic kidney disease 
(CKD) or renal failure (RF) 
CKD= 403, 404, 250, 581-583, V42; RF= 584-586, 638, 639, 
403, 404  
Cancer (malignancy) Colon (153), breast (174), lung (162), prostrate (185), 
melanoma(172), myeloma (203), kidney (189), bladder (188), 
HIV infection (042) 
Hepatic  (liver disease/ 
abnormal liver function) 
Acute hepatic failure or necrosis (570), hepatic encephalopathy 
(573) 
TIA= Transient ischemic attack; DVT = Deep vein thrombosis 
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APPENDIX B 
NAMCS reason for visit (RFV) codes to identify contraindications to warfarin 
(according to Coumadin package insert) 
Warfarin contraindications RFV 
code 
Description 
1. Hemorrhagic tendencies or blood 
dyscrasias 
1640 
 
2525 
Abnormalities of urine: blood in urine 
(hematuria)              
cerebrovascular disease: CVA, cerebral 
hemorrhage, stroke 
2. Active GI ulceration 1580 GI bleeding; blood in stool (melena), 
vomiting blood 
3. Recent surgery 4521 Major surgery 
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APPENDIX C 
 
List of Long-term Care Drug Database System (LTCDDS) codes used to 
determine drug exposure for NH residents with AF 
 
Drug  LTCDDS codes 
Warfarin 07930, 34775 
Aspirin 97174 (baby aspirin; 81mg), 10975 (ecotrin; 81mg), 00078 (aggrenox; asprin-
dypyridamole, 20mg/250mg), 00100 (ASA; 325mg), 93245 (halfprin; 81mg 
or 162mg) 
Clopidogrel 99033, 98086 
Ticlopidine 93192, 93362 
Dipyridamole 
NSAIDs: 
  Aspirin 
   
  Celecoxib  
  Diclofenac         
  Diflunisal 
  Etodolac 
  Fenoprofen 
  Ibuprofen 
  Indomethacin 
  Ketoprofen 
  Meclofenamate  
  Meloxicam 
  Nabumetone 
  Naproxen 
  Oxaprozin 
  Piroxicam 
  Rofecoxib 
  Salsalate 
  Sodium    
  salicylate 
  Sulindac 
  Valdecoxib 
23535, 09920 
 
51380, 00100, 02725, 25520, 23390, 12550, 04194, 21290, 02805, 41880, 
01755, 27300, 97174, 10975, 00078, 00100, 93245 
99002 
02148, 34725, 92116, 98006 
 
10126 
92051, 92124 
20210 
89050, 19675, 15395, 00597, 98043 
15590, 15600 
93432, 93312, 61100 
18558 
00048 
93132, 94179 
04382, 20285, 20290, 01838, 94125 
94127, 93399 
12193, 92145 
01048, 99067 
27405, 09925, 27407 
93140, 27340 
29998, 06935 
02014 
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APPENDIX D 
Description of the Variables Collected from Electronic Medical Records 
Variable  Variable Name Type Description 
Patient number PT_NO Discrete Unique number assigned by the researcher 
to each patient 
Observation 
number 
OBS Discrete Number assigned to observations from each 
patients 
Age AGE Continuous Exact value in years obtained from the 
medical records 
Sex SEX Categorical Male or Female 
Race RACE Categorical White, African-American or Hispanic 
Indication for 
warfarin use 
IND Categorical  Indication for which patient was prescribed 
warfarin- atrial fibrillation; atrial fibrillation 
or atrial flutter; atrial flutter; deep vein 
thrombosis or pulmonary embolism; 
mechanical value replacement; other 
conditions 
INR goal INR_GOAL Continuous  Recommended INR therapeutic range  
Warfarin 
Regimen 
WAR_REGIMEN Continuous Daily and weekly warfarin dose recorded 
from anticoagulation clinic notes 
Antibiotic 
prescribed 
ANT Categorical Antibiotic generic name recorded from 
outpatient pharmacy prescription record 
Antibiotic start 
date 
ANT_START Date Date antibiotic was started; verified from 
patient medical record 
Dose and 
duration of 
antibiotic use 
ANT_DOSE_DUR  
Continuous 
Antibiotic dose and duration recorded from 
outpatient pharmacy prescription record; 
verified from patient medical record 
Indication for 
antibiotic use 
IND_ANT Categorical Indication for which antibiotic was 
prescribed to patient- upper respiratory 
infections (URIs); pulmonary infections; 
urinary tract infections (UTIs); skin; other 
infections 
Pre-antibiotic 
INR 1 
PRE_INR_1 Continuous INR value collected during the 4-week 
period before start of antibiotic; exact INR 
values as recorded in the clinical notes (if 
available) 
Date of pre-
antibiotic INR 
1 
DATE_1 Date Date pre-antibiotic INR value was recorded 
in clinical notes 
Pre-antibiotic 
INR 2 
PRE_INR_2 Continuous INR value collected during the 4-week 
period before start of antibiotic; exact INR 
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Variable  Variable Name Type Description 
values as recorded in the clinical notes 
Date of pre-
antibiotic INR 
2 
DATE_2 Date Date pre-antibiotic INR value was recorded 
in clinical notes 
Post-antibiotic 
INR 1 
POST_INR_1 Continuous 1st INR value collected during the duration 
of use of antibiotic or during the 14-day 
period following discontinuation of 
antibiotic 
Date of post-
antibiotic INR 
1  
DATE_3 Date Date post-antibiotic INR value was 
recorded in clinical notes 
Post-antibiotic 
INR 2 
POST_INR_2 Continuous 2nd INR value collected during the duration 
of use of antibiotic or during the 14-day 
period following discontinuation of 
antibiotic (if available) 
Date of post-
antibiotic INR 
2 
DATE_4 Date Date post-antibiotic INR value was 
recorded in clinical notes 
Number of 
concurrent 
medications 
TOTAL_MEDS Continuous Counted number of medications taken by 
each patient (from medical records) 
Number of co-
morbidities 
TOTAL_COMOR Continuous Number of all co-existing conditions (from 
medical records) 
Warfarin dose 
withheld 
WAR_HELD Categorical ‘Yes’ for warfarin dose withheld or ‘No’ for 
dose not withheld 
Warfarin dose 
reduced 
WAR_REDUCED Categorical ‘Yes’ for warfarin dose reduced or ‘No’ for 
dose not reduced 
New warfarin 
dose regimen 
WAR_NEW_REG Continuous Change in warfarin dose regimen 
Minor bleeding 
event 
MINOR_BLEED Categorical ‘Yes’ for minor bleed or ‘No’ for no minor 
bleed 
Major bleeding 
event 
MAJOR_BLEED Categorical ‘Yes’ for major bleed or ‘No’ for no minor 
bleed 
Vitamin K 
administered 
VITK_AD Categorical ‘Yes’ for vitamin K administered or ‘No’ 
for vitamin K not administered 
Emergency 
department visit 
ED_VISIT Categorical ‘Yes’ for patient with emergency 
department visit, ‘No’ for no emergency 
department visit  
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APPENDIX E 
SAS codes for Repeated Measures ANOVA 
The SAS code 
/*****************************************************************************
****************REPEATED MEASURES ANOVA********************/ 
 
/*********  stacking the INR values  ****************/ 
 
data Mylib.warfarin_long; 
set Mylib.warfarin_1; 
inr = pre_inr_1; time = 1; output; 
inr = pre_inr_2; time = 2; output; 
inr = post_inr_1; time = 3; output; 
inr = post_inr_2; time = 4; output; 
drop pre_inr_1 pre_inr_2 post_inr_1 post_inr_2; 
run; 
 
proc sort data = Mylib.warfarin_long; 
by ant; 
run; 
 
/*To test for effect of antibiotics on INR values over time, is there an interaction between 
antibiotic and time*/ 
 
 /**********  Method 1: Compound Symmetry  ****************/ 
proc mixed data = Mylib.warfarin_long; 
class ant time obs; 
model inr = ant time ant*time; 
repeated time / subject = obs type = cs; 
lsmeans time*ant/ diff adjust = tukey cl slice=ant; 
title 'antibiotic interaction: CS'; 
run; 
 
/**************Method 2: Auto-regressive***************/ 
proc mixed data = mylib.warfarin_long; 
class ant time obs; 
model inr = ant time ant*time; 
repeated time / subject = obs type = ar(1); 
lsmeans time*ant/ diff adjust = tukey cl slice=ant; 
title 'antibiotic interaction: AR(1)'; 
run; 
 
 
 /*****************Method 3: Unstructured*************/ 
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ods trace on; 
 ods graphics on; 
 ods output Tests3= Mylib.type3test; 
 ods output LSmeans=Mylib.means; 
 ods output Slices=Mylib.slices; 
 ods output Diffs=Mylib.difference; 
 
proc mixed data = mylib.warfarin_long; 
class ant time obs; 
model inr = ant time ant*time; 
repeated time / subject = obs type = un; 
lsmeans time*ant/ diff adjust = tukey cl slice=ant; 
title 'antibiotic interaction: UN'; 
run; 
 
ods graphics off; 
ods trace off; 
 
 
Definition of the variable names in the Proc Mixed code 
ant = the type of antibiotic received i.e. amoxicillin, azithromycin, cephalexin,    ciprofloxacin, 
levofloxacin, moxifloxacin 
time = 4 time periods during which INR values were recorded; first 2 INR values were recorded 
pre-antibiotic use, last 2 INR values were recorded post-antibiotic use 
obs = patient 
 
Description of the Proc Mixed code 
Data = the name of the dataset to be analyzed 
Class = the classification variables to be used in the analysis, i.e. the categorical variables are 
obs, ant and time. 
Model = the statement that specifies the model for the analysis. The first variable, i.e. INR, is the 
response variable. Following the ‘=’ are the explanatory variables, i.e. the variables which may 
be affecting the INR values. In this study we are looking to see if change in INR values over time 
is different for different antibiotics, so an interaction term ant*time is added in the model 
statement. Since this interaction term was found to be significant, the results are interpreted 
accordingly.  
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Repeated = is used to specify the correlation structure of the data. Here there are repeated 
measures on each patient. The obs variable uniquely identifies the patients. The repeated 
statement is followed by the repeated effect, here time. The subject = obs is used to specify the 
subject effect and the type = UN option is used to specify the correlation structure for the 
variance-covariance matrix.   
All 3 covariance structures (CS, AR(1) and UN) are used and the model with the minimum AIC 
values is chosen (UN).  
Random = specifies the variable which is causing the random variability within the study, i.e. 
obs (patient) in this case. In most analyses, the subject is conceived to be a random representative 
of all possible subjects. Year or time is the fixed-effect, that is, its values represent specific levels 
of the factor and these values are “fixed” in the sense that out hypotheses refer to comparisons 
between these specific levels. Since the final model includes both fixed and random effects, the 
model is termed a “mixed model”.  
LSmeans = the statistical method used to test the differences in INR values across the time 
points and between antibiotics, i.e. comparing the estimated adjusted mean value of the INR 
values between the different antibiotics and across the different time points (2 and 3 time points 
are of interest for this study).  
Ods output = outputs the results of the individual lsmeans to the ‘means’ dataset in the Mylib 
folder, and the difference of the lsmeans computed using test slices is outputted to the 
‘differences’ dataset in the Mylib folder. 
Information obtained from the SAS log 
If the model is correct there will be a note in the log ‘Convergence criteria met’. If not, then the 
model need to be changed or the assumption of normality of the data is incorrect. In this case the 
convergence criteria was met using all 3 covariance structures and the model that gave the 
minimum AIC values (i.e. UN) was chosen. 
 
 
 
 
 
 
	   151	  
VITA	  
	  
PARINAZ	  GHASWALLA	  
Date	  and	  place	  of	  birth:	  June	  5,	  1985;	  Mumbai,	  India	  
Citizenship:	  Indian	  
Email:	  ghaswallapk@vcu.edu	  
EDUCATION	  
August	  2007-­‐	  
Present	  	   PhD	  Candidate	  (Expected	  graduation:	  December	  2011)	  
Pharmacotherapy	  and	  Outcomes	  Sciences	  
	   	   Virginia	  Commonwealth	  University,	  School	  of	  Pharmacy,	  Richmond,	  VA	  
Specialization:	  Geriatric	  Pharmacotherapy	  (Cumulative	  GPA:	  3.9)	  
	  
Dissertation	  title:	  Medication-­‐related	  problems	  in	  older	  adults:	  a	  focus	  on	  underuse	  of	  
warfarin	  and	  warfarin-­‐antibiotic	  interactions.	  	  
• Encompasses	  two	  projects:	  
1. Warfarin	  Use	  in	  Nursing	  Home	  Residents:	  Results	  from	  the	  2004	  National	  
Nursing	  Home	  Survey	  
2. Warfarin-­‐Antibiotic	  Interactions	  in	  Older	  Adults	  of	  an	  Outpatient	  
Anticoagulation	  Clinic	  
August	  2003-­‐	  
June	  2007	   Bachelor	  of	  Pharmaceutical	  Science	  	  
	   	   University	  of	  Mumbai,	  Institute	  of	  Chemical	  Technology	  
Mumbai,	  India	  	  
	  
PROFESSIONAL	  EXPERIENCE	  
January	  2011	  –	  
	  June	  2011	   Research	  Assistant	  	  
	   	   Veterans	  Affair	  Medical	  Center,	  McGuire	  Hospital,	  Richmond,	  VA	  
• Designed	  a	  research	  study,	  prepared	  and	  submitted	  protocol	  for	  the	  same	  to	  the	  VA	  
IRB	  office	  
• Underwent	  training	  for	  using	  the	  VA’s	  electronic	  medical	  recording	  system	  
• Data	  collection,	  analyses	  and	  authoring	  the	  manuscript	  of	  the	  research	  study	  
February	  2008-­‐	  
October	  2008	  	   Project	  Specialist	  
	   	   Virginia	  Health	  Quality	  Center	  (VHQC),	  Richmond,	  VA	  
• Specialist	  on	  a	  CMS-­‐funded	  national	  drug	  safety	  project	  to	  reduce	  rates	  of	  
potentially	  inappropriate	  medications	  (PIMs)	  and	  drug-­‐drug	  interactions	  (DDIs)	  in	  
older	  adults,	  across	  25	  physician	  practices	  in	  Virginia.	  Target	  reduction	  rate	  of	  5%	  in	  
PIMs	  and	  DDIs	  was	  met	  at	  the	  end	  of	  the	  project.	  
• Assisted	  with	  proposal	  development	  for	  submission	  to	  CMS	  
• Authored	  an	  introductory	  white	  paper	  for	  participating	  physician	  practices	  titled	  
‘Strategy	  map	  for	  reducing	  drug-­‐drug	  interactions	  and	  potentially	  inappropriate	  
medication	  events’	  	  
	   152	  
• Developed	  interventions	  and	  educational	  materials	  specifically	  targeting	  physician	  
practices	  
• Developed	  patient	  safety	  flyers	  for	  VHQC	  website	  and	  physician	  practices,	  through	  
extensive	  literature	  review,	  on	  the	  following:	  
o Polypharmacy	  and	  Drug	  Interactions’	  
o ‘Warfarin-­‐Drug	  Interactions	  in	  Older	  Adults’	  
o ‘Drug	  Interactions	  and	  Safety	  of	  New	  Oral	  Anticoagulants:	  Focus	  on	  
Dabigatran	  &	  Rivaroxaban’	  
o ‘Serotonin	  Syndrome	  in	  Older	  Adults:	  Causes,	  Diagnosis	  and	  Treatment	  
Options’	  
August	  2007-­‐	  
May	  2010	  	  	  	  	  	  	  	  	  	  	  	  Graduate	  Teaching	  Assistant	  
	   	   Virginia	  Commonwealth	  University	  
• Department	  of	  Biostatistics,	  School	  of	  Medicine	  
o Taught	  and	  reviewed	  biostatistical	  methods	  for	  graduate-­‐level	  students	  	  
• Department	  of	  Pharmacy,	  School	  of	  Pharmacy	  
o Courses:	  Clinical	  Therapeutic	  Modules	  (Cardiovascular,	  Endocrinology,	  
Neurology,	  Women’s	  Health,	  Special	  Populations)	  
May	  2006-­‐	  
June	  2006	   Summer	  Intern	  
	   	   Pfizer	  Limited,	  Mumbai,	  India	  
	  
PUBLICATIONS	  AND	  PRESENTATIONS	  
Manuscripts	  
• Ghaswalla	  PK,	  Harpe	  SE,	  Slattum	  PW,	  “Warfarin	  Use	  in	  US	  Nursing	  Homes:	  Results	  from	  the	  
2004	  National	  Nursing	  Home	  Survey”.	  	  
Original	  research	  paper	  accepted	  for	  publication	  by	  the	  American	  Journal	  of	  Geriatric	  
Pharmacotherapy.	  In	  press.	  	  
	  
• Ghaswalla	  PK,	  Slattum	  PW,	  Harpe	  SE,	  Tassone	  DE,	  “Warfarin-­‐Antibiotic	  Interactions	  in	  Older	  
Adults	  of	  an	  Outpatient	  Anticoagulation	  Clinic”.	  
Original	  research	  paper	  to	  be	  submitted	  in	  January	  2012.	  
	  
• Ghaswalla	  PK,	  Slattum	  PW,	  “Effect	  of	  Age	  on	  Warfarin-­‐Antibiotic	  Interactions	  in	  Older	  Adults”	  
Review	  paper	  –	  to	  be	  submitted	  to	  The	  American	  Journal	  of	  Geriatric	  Pharmacotherapy,	  
December	  2011.	  
	  
Posters	  
• Ghaswalla	  PK,	  Slattum	  PW,	  Harpe	  SE,	  Tassone	  DM,	  ‘Warfarin-­‐Antibiotic	  Interactions	  in	  Older	  
Adults	  of	  an	  Outpatients	  Anticoagulation	  Clinic’.	  	  
o Accepted	  for	  poster	  presentation	  at	  the	  2012	  American	  Society	  of	  Clinical	  Pharmacology	  
and	  Therapeutics	  (ASCPT)	  Annual	  Meeting	  (Mach	  2012)	  
• Ghaswalla	  PK,	  Slattum	  PW,	  Harpe	  SE,	  Tassone	  DM,	  ‘Retrospective	  Assessment	  of	  Potential	  Drug	  
Interactions	  between	  Warfarin	  and	  Antibiotics	  in	  Older	  Adults’.	  	  
	   153	  
o Presented	  at	  the	  Research	  &	  Career	  Day,	  VCU	  School	  of	  Pharmacy	  (October	  2011)	  and	  
the	  14th	  Annual	  VCU	  Graduate	  Student	  Research	  Symposium	  &	  Exhibit	  (April	  2011)	  
• Ghaswalla	  PK,	  Slattum	  PW,	  Harpe	  SE,	  Tassone	  DM,	  ‘Warfarin	  Use	  in	  US	  Nursing	  Homes:	  Results	  
from	  the	  2004	  National	  Nursing	  Home	  Survey’.	  	  
o Presented	  at	  the	  31st	  Annual	  Southern	  Gerontological	  Society	  Meeting	  (April	  2010),	  the	  
13th	  Annual	  VCU	  Graduate	  Student	  Research	  Symposium	  &	  Exhibit	  (April	  2010)	  	  
• Dotiwala	  ZJ,	  Ghaswalla	  PK,	  ‘Use	  of	  warfarin	  and	  potentially	  interacting	  medications	  in	  US	  
nursing	  home	  residents’.	  	  
o Presented	  at	  the	  Midwest	  Social	  &	  Administrative	  Pharmacy	  Conference,	  Iowa	  (July	  
2010)	  
	  
Other	  relevant	  work:	  
• Conducted	  data	  analysis	  for	  a	  study	  titled	  ‘Influence	  of	  Continuous	  Venovenous	  Hemofiltration	  
and	  Continuous	  Venovenous	  Hemodiafiltration	  on	  the	  Disposition	  of	  Doripenem’	  published	  in	  
Antimicrobial	  Agents	  and	  Chemotherapy,	  55:3,	  Mar	  2011.	  
	  
INVITED	  JOURNAL	  REVIEWER	  EXPERIENCE	  
• Reviewer	  for	  The	  Annals	  of	  Pharmacotherapy	  
	  
SOFTWARE	  PROFICIENCY	  
• Data	  analysis	  software	  programs:	  SAS	  9.2,	  SPSS	  17.0,	  JMP	  8.0,	  nQUERY	  7.0	  
• PK/PD	  modeling	  software:	  SCIENTIST®	  
• Microsoft	  Office	  Suite	  2007	  
	  
HONORS	  AND	  AWARDS	  
• VCU	  Graduate	  School	  Thesis/	  Dissertation	  Assistantship	  Award	  (2010-­‐2011)	  
• Invited	  to	  membership	  to	  Honor	  Society	  of	  Phi	  Kappa	  Phi	  for	  academic	  excellence	  (Oct	  ‘08	  
Present)	  
• Who’s	  Who	  Among	  Students	  in	  American	  Universities	  and	  Colleges	  Award	  (April	  2010	  &	  2011)	  
	  
LEADERSHIP	  EXPERIENCE	  
• Elected	  to	  the	  post	  of	  President	  for	  the	  Graduate	  Student	  Association	  of	  the	  Dept.	  of	  
Pharmacotherapy	  and	  Outcomes	  Sciences,	  VCU	  School	  of	  Pharmacy	  (August	  2009-­‐	  July	  2010)	  	   	  
 	  
